https://www.pharmaceutical-technology.com/data-insights/ovid-therapeutics-gets-grant-for-treating-aural-fullness-or-hearing-loss-with-specific-compound/ 2023-12-06T04:11:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/denali-therapeutics-files-patent-for-crystalline-forms-of-a-specific-compound-and-their-preparation/ 2023-12-05T13:28:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abivax-gets-grant-for-patent-granted-for-compound-to-treat-rna-virus-infection/ 2023-12-06T04:09:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/voyager-therapeutics-files-patent-for-therapeutic-use-of-adeno-associated-virus-particles-for-disease-prevention-treatment/ 2023-12-19T12:41:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/agios-pharmaceuticals-files-patent-for-method-for-treating-lymphoma-using-anti-cancer-agent-and-therapy/ 2023-12-05T13:27:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gsk-gets-grant-for-inhibitors-of-dna-methyltransferase-1-activity-in-cancer-treatment/ 2023-12-06T04:08:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/radius-health-files-patent-for-analyzing-and-treating-abaloparatide-isomers-in-samples/ 2023-12-19T12:40:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zevra-therapeutics-files-patent-for-method-of-using-a-nk-antagonist-to-treat-vasomotor-symptoms-in-cancer-patients/ 2023-12-05T13:27:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/eli-lilly-and-co-gets-grant-for-patent-granted-for-medication-delivery-device-with-dose-sensing/ 2023-12-06T04:07:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gilead-sciences-files-patent-for-treatment-of-viral-infections-using-a-non-coding-dna-sequence/ 2023-12-05T13:26:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jubilant-pharmova-files-patent-for-the-patent-filed-is-for-a-method-of-treating-netosis/ 2023-12-19T12:40:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/exelixis-files-patent-for-the-patent-is-filed-for-a-method-of-predicting-cancer-treatment-response/ 2023-12-19T12:39:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lonza-group-files-patent-for-method-for-reprogramming-mammalian-somatic-cells-using-synthetic-transcription-factors/ 2023-12-05T13:24:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/evotec-files-patent-for-novel-interferon-associated-antigen-binding-proteins-for-treating-hbv-infection/ 2023-12-05T13:23:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ardelyx-files-patent-for-method-for-generating-2d-intestinal-cell-cultures-without-cancer-cells/ 2023-12-19T12:39:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/actinium-pharmaceuticals-files-patent-for-the-patent-is-filed-for-compositions-and-methods-for-treating-cancers/ 2023-12-19T12:38:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/orexo-gets-grant-for-nasal-applicator-device-for-delivering-epinephrine-powder-to-nasal-mucosa/ 2023-12-06T04:03:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/argenx-files-patent-for-antibodies-for-inhibiting-tumor-cell-growth-by-binding-cd70/ 2023-12-05T13:22:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/inflarx-files-patent-for-the-patent-filed-is-for-humanized-anti-c5a-antibodies/ 2023-12-05T13:18:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/takeda-pharmaceutical-files-patent-for-treating-schizophrenia-with-a-specific-compound-in-high-dosage/ 2023-12-19T12:36:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sorrento-therapeutics-gets-grant-for-variant-anti-ox40-antibody-for-enhancing-t-cell-expansion/ 2023-12-19T12:49:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/senju-pharmaceutical-gets-grant-for-medicament-for-treating-fuchs-endothelial-corneal-dystrophy-using-tgf-beta-signal-inhibiting-agent/ 2023-12-06T04:03:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sorrento-therapeutics-files-patent-for-method-for-treating-pulmonary-inflammatory-disease-by-neural-ablation/ 2023-12-19T12:35:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/omeros-files-patent-for-a-patent-filed-for-a-method-of-treating-autoimmune-disorders/ 2023-12-05T13:12:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/selecta-biosciences-gets-grant-for-patent-granted-for-a-method-of-administering-immunosuppressant-nanocarriers-with-antigen/ 2023-12-19T12:48:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/incyte-files-patent-for-method-for-reducing-itch-in-patients-with-atopic-dermatitis/ 2023-12-05T13:11:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anavex-life-sciences-files-patent-for-the-patent-is-filed-for-a-method-of-treating-seizures/ 2023-12-19T12:34:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ptc-therapeutics-gets-grant-for-patent-granted-for-pharmaceutical-composition-containing-crystalline-form-d-of-sepiapterin/ 2023-12-06T04:01:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/amarin-corp-files-patent-for-method-of-reducing-triglycerides-in-a-subject-on-atorvastatin-therapy/ 2023-12-19T12:26:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/grunenthal-files-patent-for-method-of-treating-neuropathic-condition-with-high-concentration-capsaicin/ 2023-12-05T13:10:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/teladoc-health-gets-grant-for-remote-presence-interfaces-for-controlling-telepresence-devices-on-portable-electronic-devices/ 2023-12-19T12:48:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/alnylam-pharmaceuticals-files-patent-for-antisense-polynucleotide-agent-for-inhibiting-angiotensinogen-expression/ 2023-12-19T12:25:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kineta-gets-grant-for-inhibition-of-usp14-for-treating-proteostasis-dysfunction/ 2023-12-06T04:00:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/faron-pharmaceuticals-files-patent-for-stable-formulation-of-anti-clever-1-antibody-for-disease-treatment/ 2023-12-05T13:09:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/spectrum-pharmaceuticals-files-patent-for-method-for-promoting-anti-tumor-immune-response-using-encapsulated-il-12/ 2023-12-19T12:23:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rigel-pharmaceuticals-files-patent-for-kinase-inhibitory-compounds-for-treating-rip1-associated-diseases/ 2023-12-05T13:08:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/les-laboratoires-servier-files-patent-for-anti-cd73-antibodies-for-treating-diseases-especially-cancer/ 2023-12-19T12:23:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/medigen-biotechnology-files-patent-for-the-patent-filed-is-for-monoclonal-antibodies-against-sars-cov-2/ 2023-12-05T13:07:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/blueprint-medicines-gets-grant-for-compound-for-treating-cancer/ 2023-12-19T12:47:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/alector-files-patent-for-antibodies-for-preventing-or-treating-tmem106b-related-conditions/ 2023-12-19T12:22:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/blueprint-medicines-files-patent-for-crystalline-solid-form-of-compound-i-or-its-salt/ 2023-12-05T13:05:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kinnate-biopharma-files-patent-for-inhibitors-of-receptor-tyrosine-kinase-effector-for-disease-treatment/ 2023-12-05T13:04:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sword-health-files-patent-for-method-for-assessing-tracker-positions-on-a-person-s-body/ 2023-12-19T12:21:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dyne-therapeutics-files-patent-for-the-patent-is-filed-for-a-complex-that-promotes-dmd-gene-expression/ 2023-12-19T12:20:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sana-biotechnology-files-patent-for-a-binding-agent-for-treating-virus-infection-with-reduced-inflammation/ 2023-12-05T13:03:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/guangzhou-kingmed-diagnostics-group-files-patent-for-method-for-detecting-uniparental-disomy-using-ngs-trio-sequencing/ 2023-12-05T13:00:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/innocare-pharma-files-patent-for-heterocyclic-compounds-as-immunomodulators-for-treating-diseases/ 2023-12-19T12:19:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kymera-therapeutics-files-patent-for-compounds-compositions-and-methods-of-using-the-same/ 2023-12-19T12:18:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/igm-biosciences-files-patent-for-modified-j-chain-antibodies-with-extraneous-binding-moiety/ 2023-12-05T12:59:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/celularity-files-patent-for-method-of-isolating-exosomes-from-placenta-or-portion-thereof/ 2023-12-05T12:57:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/springworks-therapeutics-files-patent-for-chlorinated-tetralin-compounds-and-pharmaceutical-compositions/ 2023-12-19T12:16:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ikena-oncology-files-patent-for-ahr-agonists-and-their-use-in-compositions-and-methods/ 2023-12-19T12:15:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/wuxi-biologics-cayman-files-patent-for-genetically-modified-cell-line-producing-mannose-terminated-glycoprotein/ 2023-12-05T12:56:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cue-biopharma-files-patent-for-t-cell-modulatory-multimeric-polypeptides-with-variant-immunomodulatory-polypeptides/ 2023-12-05T12:55:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vir-biotechnology-files-patent-for-antibodies-for-neutralizing-hepatitis-b-and-hepatitis-d-infection/ 2023-12-19T12:14:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/wuxi-apptec-files-patent-for-a-patent-for-a-process-of-producing-recombinant-adenoviral-particles/ 2023-12-19T12:13:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bolt-biotherapeutics-files-patent-for-immunoconjugates-for-cancer-treatment-using-elastase-substrate-peptide-linker/ 2023-12-05T12:54:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/c4-therapeutics-files-patent-for-compound-with-e3-ubiquitin-ligase-targeting-moieties-for-protein-degradation/ 2023-12-05T12:52:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aptinyx-files-patent-for-modulation-of-nmda-receptor-activity-for-treating-depression/ 2023-12-19T12:12:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lantern-pharma-files-patent-for-method-for-determining-cancer-sensitivity-to-illudin-or-illudin-analogs/ 2023-12-19T12:11:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ovid-therapeutics-files-patent-for-treatment-of-lennox-gastaut-syndrome-using-ganaxolone-oral-suspension/ 2023-12-05T12:50:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/revolution-medicines-files-patent-for-the-patent-is-filed-for-macrocyclic-compounds-inhibiting-ras-proteins/ 2023-12-05T12:51:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/biora-therapeutics-files-patent-for-treating-gastrointestinal-diseases-with-a-tnf-alpha-inhibitor/ 2023-12-19T12:10:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anges-files-patent-for-patent-filed-for-a-non-naturally-occurring-crispr-nuclease-composition/ 2023-12-19T12:09:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/precision-biosciences-files-patent-for-mitochondria-targeting-engineered-meganuclease-for-modifying-human-mitochondrial-dna/ 2023-12-05T12:46:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/kazakhstan-to-attract-150-billion-dollars-fdi-by-2029/ 2023-11-21T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/why-cop28-is-the-most-important-cop-since-the-paris-agreement-2/ 2023-11-21T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/experts-gene-therapy-potential-impact-gaucher-disease-market/ 2025-01-31T10:38:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/merck-co-bolsters-neurogenerative-portfolio-with-caraway-acquisition/ 2023-11-21T15:52:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/beigene-strikes-deal-worth-1-3bn-with-ensem-for-cdk2-inhibitor/ 2023-11-21T15:18:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/uk-launches-medicines-scheme-with-400m-earmarked-for-clinical-trials/ 2023-11-21T14:04:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-delays-assessment-of-bms-and-2seventys-car-t-therapy/ 2023-11-22T10:30:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ascendis-parathyroid-hormone-replacement-therapy-wins-european-approval/ 2023-11-21T12:39:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/the-right-tools-how-in-house-tooling-streamlines-autoinjector-manufacturing/ 2023-11-21T11:34:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/texas-ag-sues-pfizer/ 2023-11-21T10:52:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/mira-agreement-depression-therapy/ 2023-11-21T10:34:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/zevra-acer-acquisition/ 2023-11-21T08:43:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/janssen-fda-lung-cancer-therapy/ 2023-11-21T08:22:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/are-haemophilia-gene-therapies-truly-one-and-done/ 2023-11-20T22:30:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/uk-south-korea-21-billion-pounds-fdi/ 2023-11-20T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/neoimmunetech-bags-orphan-drug-tag-for-il-7-acute-radiation-syndrome-treatment/ 2023-11-20T20:13:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/wegovy-highlights-uks-complex-relationship-with-private-sector/ 2023-11-20T16:25:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/chiesi-partners-with-haisco-to-commercialise-bronchiectasis-drug/ 2023-11-20T15:15:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/takeda-wins-eu-approval-for-paediatric-use-of-takhzyro-in-hae/ 2023-11-20T14:31:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/oxurion-to-file-for-bankruptcy-following-trial-failure/ 2023-11-20T13:45:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/pfizer-licenses-small-molecule-drug-delivery-technology-from-serina/ 2023-11-20T11:49:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/monash-university-prostate-cancer-therapy/ 2023-11-20T11:30:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/astrazeneca-evinova-digital-health/ 2023-11-20T10:59:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/bayer-recall-vitrakvi-us/ 2023-11-20T09:06:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ec-approves-beigene-brukinsa/ 2023-11-20T08:28:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/antibody-drug-conjugates-targeted-therapies/ 2023-11-20T06:59:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/hampton-court-palace-venue-chosen-global-investment-summit/ 2023-11-19T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/chatgpt-one-year-on-how-have-businesses-been-affected/ 2023-11-19T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mrna-3705-moderna-net-present-value/ 2024-05-16T02:00:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rpa-501-rocket-pharmaceuticals-net-present-value/ 2024-06-13T18:54:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pxvx-0317-bavarian-nordic-net-present-value/ 2024-12-13T02:53:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/diazoxide-choline-cr-soleno-therapeutics-net-present-value/ 2024-06-13T18:51:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/palazestrant-olema-pharmaceuticals-net-present-value/ 2024-05-16T02:08:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/reboxetine-axsome-therapeutics-net-present-value/ 2024-05-16T02:05:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tern-501-terns-pharmaceuticals-net-present-value/ 2024-12-13T02:50:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pirtobrutinib-eli-lilly-and-co-refractory-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2025-01-20T02:15:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pirtobrutinib-eli-lilly-and-co-relapsed-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2025-01-20T02:15:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/golexanolone-umecrine-cognition-hepatic-encephalopathy-likelihood-of-approval-2/ 2025-01-20T02:15:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/glofitamab-f-hoffmann-la-roche-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2025-01-19T18:26:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kl-1333m-abliva-myoclonic-epilepsy-with-ragged-red-fibers-merrf-syndrome-likelihood-of-approval/ 2025-01-19T18:26:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/povetacicept-alpine-immune-sciences-idiopathic-thrombocytopenic-purpura-immune-thrombocytopenic-purpura-likelihood-of-approval-2/ 2024-12-25T17:58:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mrna-1083-moderna-influenza-a-virus-h3n2-subtype-infections-likelihood-of-approval-3/ 2025-01-19T18:08:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/uncategorized/mrna-1083-moderna-influenza-a-virus-h3n2-subtype-infections-likelihood-of-approval-2/ 2023-11-18T20:11:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mrna-1083-moderna-influenzavirus-b-infections-likelihood-of-approval-2/ 2025-01-19T18:08:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mrna-1083-moderna-influenza-a-virus-h1n1-subtype-infections-likelihood-of-approval-2/ 2025-01-19T18:08:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aphd-012-aphaia-pharma-pre-diabetes-impaired-glucose-tolerance-likelihood-of-approval-2/ 2025-01-19T18:07:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/povetacicept-alpine-immune-sciences-iga-nephropathy-berger-s-disease-likelihood-of-approval-2/ 2024-12-25T17:36:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/povorcitinib-phosphate-incyte-vitiligo-likelihood-of-approval-2/ 2024-12-25T17:33:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/daridorexant-hydrochloride-idorsia-pharmaceutical-post-traumatic-stress-disorder-ptsd-likelihood-of-approval-2/ 2024-12-25T17:27:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mirikizumab-eli-lilly-and-co-crohn-s-disease-regional-enteritis-likelihood-of-approval-2/ 2024-12-25T17:25:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vorinostat-merck-vulvar-cancer-likelihood-of-approval/ 2025-01-19T17:24:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sotatercept-merck-pulmonary-hypertension-likelihood-of-approval/ 2025-01-19T17:21:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aficamten-cytokinetics-hypertrophic-cardiomyopathy-likelihood-of-approval/ 2025-01-19T17:16:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ap-303-shanghai-alebund-pharmaceuticals-diabetic-nephropathy-likelihood-of-approval-2/ 2024-12-25T17:14:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/daridorexant-hydrochloride-idorsia-pharmaceutical-obstructive-sleep-apnea-likelihood-of-approval/ 2024-06-14T01:30:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kl-1333m-abliva-mitochondrial-diseases-likelihood-of-approval/ 2025-01-19T16:53:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brensocatib-insmed-hidradenitis-suppurativa-likelihood-of-approval/ 2025-01-19T16:51:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brensocatib-insmed-hidradenitis-suppurativa-likelihood-of-approval-2/ 2024-12-25T17:04:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tlm-001-therillume-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2025-01-20T16:43:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/uncategorized/ibi-334-innovent-biologics-head-and-neck-cancer-squamous-cell-carcinoma-likelihood-of-approval/ 2023-11-18T04:25:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/huc-2364-huons-reflux-esophagitis-gastroesophageal-reflux-disease-likelihood-of-approval/ 2023-11-18T04:20:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bnt-325-duality-biologics-shanghai-fallopian-tube-cancer-likelihood-of-approval/ 2025-01-20T16:42:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bb-1705-bliss-biopharmaceutical-hangzhou-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2025-01-20T16:42:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bb-1705-bliss-biopharmaceutical-hangzhou-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-20T16:42:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bb-1705-bliss-biopharmaceutical-hangzhou-gastric-cancer-likelihood-of-approval/ 2025-01-20T16:42:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bb-1705-bliss-biopharmaceutical-hangzhou-head-and-neck-cancer-likelihood-of-approval/ 2025-01-20T16:42:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dzd-8586-dizal-pharmaceutical-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2025-01-20T16:42:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tsc-204-hla-a-02-01-tscan-therapeutics-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-20T16:42:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/grm-grunenthal-inflammation-likelihood-of-approval/ 2025-01-20T16:42:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nb-003-newbay-medical-technology-metastatic-melanoma-likelihood-of-approval/ 2024-09-09T04:33:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dronabinol-igc-pharma-dementia-associated-with-alzheimer-s-disease-likelihood-of-approval/ 2025-01-20T16:25:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kp-1077-zevra-therapeutics-idiopathic-hypersomnia-ih-likelihood-of-approval/ 2025-01-20T16:25:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sm-020-dermbiont-dermatosis-likelihood-of-approval/ 2025-01-20T16:25:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/measles-rubella-vaccine-vaxxas-rubella-german-measles-likelihood-of-approval/ 2023-11-18T03:51:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/measles-rubella-vaccine-vaxxas-measles-likelihood-of-approval/ 2023-11-18T03:51:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/eg-017-changchun-jinsai-pharmaceutical-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2025-01-20T16:25:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/edaravone-suzhou-auzone-biological-technology-amyotrophic-lateral-sclerosis-likelihood-of-approval/ 2025-01-20T16:25:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cb-06036-shanghai-zhimeng-biopharma-hepatitis-b-likelihood-of-approval/ 2025-01-20T16:25:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ab-801-arcus-biosciences-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-02-22T00:41:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dexamethasone-sodium-phosphate-avm-biotechnology-natural-killer-cell-lymphomas-likelihood-of-approval/ 2025-01-20T16:25:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/thn-391-therini-bio-dementia-likelihood-of-approval/ 2025-01-20T16:25:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tiratricol-egetis-therapeutics-allan-herndon-dudley-syndrome-monocarboxylate-transporter-8-deficiency-likelihood-of-approval/ 2025-01-20T16:25:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ff-10158-advanced-accelerator-applications-recurrent-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2025-01-20T16:25:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nvg-291-nervgen-pharma-spinal-cord-injury-likelihood-of-approval/ 2025-01-20T16:24:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/povorcitinib-phosphate-incyte-prurigo-likelihood-of-approval/ 2025-01-20T16:24:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zilganersen-sodium-ionis-pharmaceuticals-alexander-disease-likelihood-of-approval/ 2025-01-20T16:24:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/car-t-anixa-biosciences-epithelial-ovarian-cancer-likelihood-of-approval/ 2025-01-20T16:24:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/car-t-anixa-biosciences-peritoneal-cancer-likelihood-of-approval/ 2025-01-20T16:24:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/car-t-anixa-biosciences-fallopian-tube-cancer-likelihood-of-approval/ 2025-01-20T16:24:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hb-002-1t-huabo-biopharm-shanghai-extrahepatic-bile-duct-cancer-likelihood-of-approval/ 2023-11-18T03:14:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ivonescimab-akeso-metastatic-biliary-tract-cancer-likelihood-of-approval/ 2025-01-20T16:24:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/furmonertinib-mesylate-arrivent-biopharma-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-06-19T05:32:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vibostolimab-merck-non-small-cell-lung-cancer-likelihood-of-approval/ 2023-11-18T03:01:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/golidocitinib-dizal-pharmaceutical-sezary-syndrome-likelihood-of-approval/ 2025-01-20T16:24:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/golidocitinib-dizal-pharmaceutical-peripheral-t-cell-lymphomas-ptcl-likelihood-of-approval/ 2025-01-20T16:24:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/golidocitinib-dizal-pharmaceutical-cutaneous-t-cell-lymphoma-likelihood-of-approval/ 2025-01-20T16:24:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/evt-801-kazia-therapeutics-ovarian-cancer-likelihood-of-approval/ 2025-01-20T16:24:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bnt-211-biontech-esophageal-cancer-likelihood-of-approval/ 2024-07-05T06:37:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ec-5026-eicosis-inflammatory-pain-likelihood-of-approval/ 2025-01-20T16:23:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ec-5026-eicosis-diabetic-neuropathic-pain-likelihood-of-approval/ 2025-01-20T16:23:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/apitegromab-scholar-rock-obesity-likelihood-of-approval/ 2024-07-05T06:37:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vimseltinib-deciphera-pharmaceuticals-tenosynovial-giant-cell-tumor-likelihood-of-approval/ 2025-01-20T16:23:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vamorolone-reveragen-biopharma-becker-muscular-dystrophy-likelihood-of-approval/ 2025-01-20T16:23:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rimegepant-sulfate-odt-pfizer-rhinosinusitis-likelihood-of-approval/ 2025-01-20T16:23:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/omadacycline-tosylate-paratek-pharmaceuticals-mycobacterium-infections-likelihood-of-approval/ 2025-01-20T16:23:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/guadecitabine-sodium-astex-pharmaceuticals-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-20T16:23:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/e-7820-eisai-chronic-myelomonocytic-leukemia-cmml-likelihood-of-approval/ 2024-05-20T11:23:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/pd-biotech-to-pursue-pivotal-trial-in-hnscc-after-exciting-phase-ii-results/ 2023-11-17T17:19:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/chinas-nmpa-grants-conditional-approval-for-apollomics-nsclc-drug/ 2023-11-17T17:28:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/aibtl-signs-667m-licensing-deal-for-abvcs-cns-drug/ 2023-11-17T17:00:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/signal-dutch-health-investor-gilde-raises-804m-for-health-startup-fund/ 2023-11-17T16:57:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/gradalis-wins-9-9m-grant-to-fund-phase-ii-trial-for-bi-shrna-therapy/ 2023-11-17T16:05:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/astrazenecas-atp-inhibitor-truqap-wins-fda-approval-in-breast-cancer/ 2023-11-17T15:26:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/combination-contraceptive-pill-to-be-made-available-otc-in-england/ 2023-11-17T15:28:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/eli-lilly-two-billion-plant-germany-investment/ 2023-11-20T21:21:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/navigating-data-consent-in-the-era-of-connected-healthcare/ 2023-11-17T16:38:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/eli-lilly-two-billion-plant-germany-investment-2/ 2024-03-20T03:34:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/daiichi-sankyo-japan-covid-vaccine/ 2023-11-17T11:14:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/gsk-endometrial-cancer-canada/ 2023-11-17T09:59:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/micron-needle-free-vaccines/ 2023-11-17T09:47:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-approval-merck-keytruda/ 2023-11-17T09:26:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fdi-role-healthcare-industry/ 2024-03-21T03:00:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/active-fdi-companies-healthcare-industry/ 2024-03-21T03:00:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/bms-strengthens-nsclc-market-share-with-ros1-drug-augtyro/ 2023-11-16T17:47:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-approves-study-of-versamebs-mrna-therapy-in-urinary-incontinence/ 2023-11-16T16:15:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/worlds-first-crispr-based-gene-therapy-approved-for-sickle-cell-anaemia/ 2023-11-22T10:29:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/xphozah-wins-orphan-drug-designation-for-paediatric-hyperphosphatemia/ 2023-11-16T11:46:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/certa-plans-pivotal-scleroderma-trial-after-phase-ii-data-readout/ 2023-11-16T16:11:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/kite-arcellx-strategic-collaboration/ 2023-11-16T10:36:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/mhra-vertex-cystic-fibrosis-children/ 2023-11-16T10:22:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/astellas-propella-therapeutics/ 2023-11-16T09:32:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/lenz-therapeutics-graphite-bio-merger/ 2023-11-16T08:33:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fdi-bulgaria-growth-january-september-2023/ 2023-11-15T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ukraine-cooperation-memos-western-companies-investment/ 2023-11-15T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/active-fdi-companies-biotechnology-industry/ 2023-11-15T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/new-propellant-chemicals-needed-for-mdpis/ 2023-11-16T16:05:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/signal-pfizer-cuts-500-uk-jobs-in-restructuring-after-posting-q3-loss/ 2023-11-15T16:48:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/kesin-pharma-expands-antibiotic-reach-with-liquid-suspension-approval/ 2023-11-15T15:32:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/cambridge-university-spinout-raises-48m-to-advance-t-cell-therapies/ 2023-11-22T10:29:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/cop27-have-we-committed-to-our-goals/ 2023-11-15T13:27:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/evaluating-the-top-five-sterilisation-techniques-for-parenteral-packaging/ 2023-11-15T12:18:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/nhs-sets-sights-on-ending-cervical-cancer-by-2040-with-hpv-vaccine-drive/ 2023-11-15T11:44:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/atreca-downsizes-again-to-focus-on-antibody-drug-conjugate-programmes/ 2023-11-15T15:09:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/jcvi-vaccine-chickenpox-children/ 2023-11-15T11:12:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/bio-europe-2023-pharma-balances-on-shaky-financial-and-legislative-footing/ 2023-11-22T21:26:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/almirall-absci-drug-development/ 2023-11-15T11:13:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/autifony-jazz-drug-development-deal/ 2023-11-15T09:59:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/mbrace-adcs-oncology-targets/ 2023-11-15T09:38:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/cop27-have-we-committed-to-our-goals-2/ 2023-11-14T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/bahrain-opened-fdi-office-singapore/ 2023-11-14T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/the-role-of-fdi-in-the-biotechnology-industry/ 2023-11-14T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/orphelia-pushes-boundaries-with-regulatory-barriers-for-pediatric-indications/ 2023-11-15T14:15:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/telix-plans-125m-acquisition-of-radiopharmaceuticals-company-qsam/ 2023-11-14T15:59:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/nouscom-raises-72m-in-series-c-financing-round-to-develop-cancer-vaccines/ 2023-11-14T16:28:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/fda-oversees-rise-in-awarded-orphan-drug-designations-for-myelofibrosis/ 2023-11-14T15:22:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/astrazeneca-glp-1-obesity-co-morbidities/ 2023-11-14T15:16:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/reform-in-south-korea-means-progression-in-improving-time-to-reimbursement/ 2023-11-22T21:46:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/analytical-testing-ten-questions-that-accelerate-drug-development/ 2025-07-03T10:32:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/prokidney-amends-phase-iii-protocol-in-light-of-phase-ii-results/ 2023-11-14T14:34:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/teva-royalty-olanzapine-lai/ 2023-11-14T11:14:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/novartis-legend-car-t-therapies/ 2023-11-22T10:29:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/sustainability-in-biopharma-the-challenges-of-esg-2-0/ 2024-07-01T16:28:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/health-canada-ipsen-medison-bylvay/ 2023-11-14T08:54:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/vectory-neurodegenerative-disease/ 2023-11-14T09:17:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/robotics-in-pharma/ 2024-06-03T07:36:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fdi-romania-drops-by-42-per-cent-in-first-nine-months-of-2023/ 2023-11-13T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/uk-chancellor-urged-to-appoint-investment-minister-to-boost-fdi/ 2023-11-13T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/victoria-atkins-mp-takes-over-uks-department-of-health-and-social-care/ 2023-11-13T17:45:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ethris-and-heqet-team-up-for-rna-based-therapeutic-development/ 2023-11-13T15:15:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-grants-orphan-drug-designation-to-maias-glioblastoma-agent/ 2023-11-13T15:14:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/fda-approves-takeda-fruzaqla-mcrc/ 2023-11-13T15:01:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/wegovy-cuts-cardiovascular-risk-by-20-for-heart-disease-patients/ 2023-11-13T14:50:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/treatment-innovation-for-healthier-patients-and-a-healthier-planet/ 2024-03-13T17:15:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ajinomoto-acquires-forge/ 2023-11-13T10:51:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/how-can-smaller-biotechs-navigate-the-landscape-of-oncology-trials/ 2023-11-13T10:48:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/miratis-lung-cancer-treatment-chmp/ 2023-11-13T10:59:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/bio-europe-2023-barriers-remain-in-the-ai-pharma-revolution-2/ 2023-11-13T10:13:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/ft-summit-ai-regulatory-changes-health-equity/ 2023-11-13T09:25:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/uk-drug-alcohol-misuse/ 2023-11-13T08:56:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/chmp-positive-opinion-merck-keytruda/ 2023-11-13T08:55:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/eli-lilly-reiterates-point-acquisition-plans-with-tender-offer-extension/ 2023-11-10T19:34:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/innovations-powering-the-future-of-mrna-what-biomanufacturers-need-to-know/ 2023-11-10T16:17:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/valneva-wins-fda-approval-for-the-first-chikungunya-vaccine/ 2023-11-10T15:16:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/bristol-myers-squibbs-car-t-breyanzi-wins-fda-priority-review/ 2023-11-15T17:42:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/bio-europe-2023-barriers-remain-in-the-ai-pharma-revolution/ 2023-11-10T17:44:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/novartis-urticaria-drug-meets-all-endpoints-in-phase-iii-trials/ 2023-11-10T13:44:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/astrazeneca-q3-2023-profit/ 2023-11-10T11:23:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/bayer-recursion-oncology-research/ 2023-11-10T11:17:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ec-daiichi-sankyo-vanflyta-aml/ 2023-11-10T08:49:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-takeda-adzynma-approval/ 2023-11-10T09:37:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/childproof-packaging-how-things-are-changing-for-consumer-drugs/ 2023-11-09T20:11:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/active-fdi-companies-pharmaceuticals-industry/ 2023-11-09T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fdi-role-pharmaceuticals-industry/ 2023-11-09T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/astrazeneca-targets-obesity-market-with-eccogene-partnership/ 2023-11-09T16:27:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/lilly-challenges-wegovy-dominance-in-weight-loss-market-with-fda-approval/ 2023-11-10T13:07:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/aao-2023-altitude-study-promising-results-abbv-rgx-314/ 2023-11-09T15:35:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-approves-takedas-colorectal-cancer-drug-fruzaqla/ 2023-11-09T11:51:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/adicet-pauses-preclinical-programme-in-car-t-cell-pipeline-reprioritisation/ 2023-11-15T17:40:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/avid-cirm-cgt-programmes/ 2023-11-09T10:26:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/is-patient-recruitment-out-of-control/ 2024-02-12T18:05:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ascidian-funding-drug-development/ 2023-11-09T10:40:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/comment/cloud-in-pharma-qa-with-globaldata-thematic-analyst/ 2023-11-22T09:54:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/mhra-lilly-mounjaro/ 2023-11-09T09:18:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/teva-q3-2023-net-income/ 2023-11-09T09:20:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/saudi-arabia-revises-fdi-methodology-records-33-billion-dollars-in-inflows-in-2022/ 2023-11-08T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/alfasigma-opens-new-doors-in-the-us-with-intercept-acquisition/ 2023-11-08T19:44:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/putting-compliance-and-quality-at-the-heart-of-pharmaceutical-supply-chains/ 2024-02-14T15:36:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/bio-europe-2023-eu-hta-harmonisation-may-land-off-key-for-pharma/ 2023-11-08T16:00:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/biotech-accelerator-blackbird-labs-launches-with-100m-grant/ 2023-11-08T15:28:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/ecoa-roadmap-five-key-steps-to-patient-focused-drug-development/ 2023-12-04T12:38:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/pyxis-cuts-staff-by-40-and-pours-resources-into-two-cancer-therapies/ 2023-11-08T13:11:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/what-in-the-world-has-happened-since-cop27/ 2023-11-08T12:18:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/omers-snaps-up-drug-royalties-and-milestones-from-xencor-for-215m/ 2023-11-08T12:04:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/what-does-bidens-executive-order-mean-for-worldwide-ai-regulation/ 2023-11-08T12:02:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/telix-strikes-deal-to-distribute-cancer-imaging-agent-in-the-nordics/ 2023-11-08T11:55:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/bio-europe-2023-translational-funding-needed-to-spur-pharma-innovation-in-europe/ 2023-11-08T11:41:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/gilead-q3-2023-income/ 2023-11-08T10:08:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/nice-expedites-medicine-evaluations-by-17-in-current-year/ 2023-11-08T09:44:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/high-impact-milling-are-you-compromising-operator-safety/ 2023-11-08T09:42:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/dewpoint-evotec-oncology-drug/ 2023-11-08T09:40:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/jazz-pharmaceuticals-zanidatamab/ 2023-11-08T08:45:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/menarini-sciclone-orserdu-china/ 2023-11-08T09:40:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/what-in-the-world-has-happened-since-cop27-2/ 2023-11-07T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/aao-2023-allgenesis-ag-73305-for-dme/ 2023-11-07T17:21:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/aao-2023-pulsar-photon-studies-promising-results-amd-dme/ 2023-11-07T17:11:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/kirkland-ellis-top-legal-ma-adviser-q1-q3-2023/ 2023-12-12T12:00:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-warns-of-hidden-drug-ingredients-in-dr-ergins-sugarmd/ 2023-11-07T16:09:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/cell-and-gene-therapy-biotechs-face-access-hurdles-in-europe/ 2023-11-07T15:59:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/bio-europe-2023-small-oncology-biotechs-require-creative-financing-approaches/ 2023-11-07T16:06:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/innovators-nucleotide-analogues-pharmaceutical/ 2024-08-29T05:06:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/nice-advice-support-service-life-sciences/ 2023-11-07T10:52:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/landmark-bio-galapagos-oncology-car-t-cell/ 2023-11-07T10:58:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/innovators-transdermal-drug-delivery-pharmaceutical/ 2024-08-29T04:26:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/innovators-immuno-oncology-immunotherapy-radiotherapy-combination-pharmaceutical/ 2024-07-29T06:44:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/mhra-breast-cancer-prevention-drug/ 2023-11-07T09:16:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/innovators-small-molecule-kinase-inhibitors-pharmaceutical/ 2024-08-29T04:26:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/innovators-immuno-oncology-cancer-immunotherapy-pharmaceutical/ 2024-07-29T11:24:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-approval-zydus-zituvimet/ 2023-11-07T09:17:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/innovators-t-cell-binding-fusion-peptides-pharmaceutical/ 2024-08-29T03:41:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/innovators-genomics-anti-sense-oligonucleotides-pharmaceutical/ 2024-07-31T04:00:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/innovators-smac-mimetic-peptides-pharmaceutical/ 2024-08-02T09:24:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/innovators-covid-19-synthetic-covid-vaccines-pharmaceutical/ 2024-07-29T10:07:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/innovators-recombinant-virus-like-particles-vlps-pharmaceutical/ 2024-08-29T05:06:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/innovators-phenotypic-drug-screening-pharmaceutical/ 2024-08-29T04:18:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/innovators-genomics-gene-silencing-pharmaceutical/ 2024-09-09T05:57:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/innovators-rdna-expression-systems-pharmaceutical/ 2024-08-05T04:52:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/innovators-covid-19-covid-recombinant-spike-proteins-pharmaceutical/ 2024-07-29T11:12:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/innovators-protein-kinase-inhibitors-pharmaceutical/ 2024-08-29T05:06:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/innovators-protein-affinity-chromatography-pharmaceutical/ 2024-08-29T03:44:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/innovators-cell-gene-therapy-vascular-disorder-gene-therapies-pharmaceutical/ 2024-07-29T12:04:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/innovators-polysaccharide-protein-conjugate-vaccines-pharmaceutical/ 2024-08-29T03:47:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/innovators-immuno-oncology-neoepitope-prediction-pharmaceutical/ 2024-07-30T05:46:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/innovators-peptide-pharmacophores-pharmaceutical/ 2024-08-29T03:47:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/innovators-nanomedicine-mrna-delivery-lipid-nanoparticles-pharmaceutical/ 2024-07-31T07:53:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/innovators-pdk-1-inhibitors-pharmaceutical/ 2024-08-29T04:19:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/innovators-neuroprotective-drugs-pharmaceutical/ 2024-08-29T04:19:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/innovators-genomics-tert-screening-pharmaceutical/ 2024-07-31T09:24:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/innovators-neuro-degenerative-disease-therapies-pharmaceutical/ 2024-08-29T04:19:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/innovators-immuno-oncology-oncolytic-adenovirus-vectors-pharmaceutical/ 2024-07-30T08:04:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/innovators-mutant-dna-polymerases-pharmaceutical/ 2024-08-29T03:37:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/innovators-multi-functional-skin-compositions-pharmaceutical/ 2024-08-29T03:47:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/innovators-cell-gene-therapy-recombinant-aav-gene-therapy-pharmaceutical/ 2024-07-29T09:38:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/innovators-modified-vector-hiv-1-vaccines-pharmaceutical/ 2024-09-09T05:14:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/innovators-modified-nucleotide-therapies-pharmaceutical/ 2024-08-29T04:26:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/namibia-to-build-first-decarbonised-iron-plant/ 2023-11-06T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/evolution-northern-superior-gold-project/ 2023-11-06T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/german-companies-prefer-to-invest-abroad-study/ 2023-11-06T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/eyp-651-enyo-pharma-diabetic-nephropathy-likelihood-of-approval/ 2025-01-20T16:23:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/eyp-651-enyo-pharma-chronic-kidney-disease-chronic-renal-failure-likelihood-of-approval/ 2025-01-20T16:23:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cd19-targeted-car-t-therapy-chongqing-precision-biotech-granulomatosis-with-polyangiitis-wegener-s-granulomatosis-likelihood-of-approval/ 2025-01-20T16:23:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/calcium-carbonate-lansoprazole-addpharma-reflux-esophagitis-gastroesophageal-reflux-disease-likelihood-of-approval/ 2023-11-06T22:09:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/influenza-strain-a-h5n8-vaccine-gsk-influenzavirus-a-infections-likelihood-of-approval/ 2025-01-20T16:23:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/apixaban-taho-pharmaceuticals-deep-vein-thrombosis-dvt-likelihood-of-approval/ 2023-11-06T22:05:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hb-0045-huabo-biopharm-shanghai-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2025-01-20T16:23:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/artesunate-frantz-viral-therapeutics-human-papillomavirus-infections-likelihood-of-approval/ 2025-01-20T16:23:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/melpida-elpida-therapeutics-paraplegia-likelihood-of-approval/ 2024-04-19T17:41:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/nrx-and-nephron-join-hands-to-formulate-ketamine-for-depression/ 2023-11-06T19:58:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/bio-europe-2023-eli-lilly-doubles-down-on-obesity-pipelines-potential/ 2023-11-06T19:56:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/goldman-sachs-rothschild-leading-ma-financial-advisers-q1-q3-2023/ 2023-12-11T16:57:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/bms-acquires-cd33-blood-cancer-adc-from-orum-in-180m-deal/ 2023-11-06T15:59:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/aao-2023-apellis-pharmaceuticals-reveals-gale-extension-study-results-for-syfovre/ 2023-11-06T15:37:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/mirati-wins-conditional-uk-approval-for-krazati-in-nsclc/ 2023-11-06T15:10:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/innovators-microbiome-bacteriophage-therapy-pharmaceutical/ 2024-07-30T05:28:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/innovators-mirna-modulation-pharmaceutical/ 2024-08-29T05:04:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/innovators-immuno-oncology-oncolytic-viruses-pharmaceutical/ 2024-07-29T13:19:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/innovators-microencapsulated-peptide-vaccines-pharmaceutical/ 2024-08-29T04:25:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/innovators-precision-and-personalized-medicine-personalized-cancer-vaccines-pharmaceutical/ 2024-07-30T05:17:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/innovators-intracellular-receptor-modulators-pharmaceutical/ 2024-09-09T05:17:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/innovators-cell-gene-therapy-raav-production-technology-pharmaceutical/ 2024-07-29T08:04:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/korro-to-launch-on-nasdaq-after-frequency-therapeutics-merger-completion/ 2023-11-06T11:57:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/innovators-influenza-vaccine-vectors-pharmaceutical/ 2024-09-09T05:19:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/innovators-cell-gene-therapy-pancreatic-cell-transplantation-pharmaceutical/ 2024-09-30T07:42:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/innovators-engineered-multi-specific-antibodies-pharmaceutical/ 2024-08-29T03:34:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/innovators-cell-gene-therapy-lentiviral-vectors-pharmaceutical/ 2024-07-29T08:50:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/innovators-immunogenic-fusion-proteins-pharmaceutical/ 2024-08-29T05:04:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/gc-biopharma-anthrax-vaccine/ 2023-11-06T10:48:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/innovators-cell-gene-therapy-ipscs-pharmaceutical/ 2024-07-31T12:10:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/innovators-glp-1-analogues-pharmaceutical/ 2024-08-02T07:25:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/lupin-zydus-liver-drug-india/ 2023-11-06T10:45:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/lactocore-outlines-plans-for-peptide-therapy-in-anxiety-disorders/ 2023-11-06T15:04:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/lactocore-outlines-plans-for-peptide-therapy-in-anxiety-disorders-2/ 2023-11-09T18:16:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/innovators-cell-gene-therapy-gene-therapy-viral-vectors-pharmaceutical/ 2024-07-29T08:37:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/innovators-expression-plasmids-pharmaceutical/ 2024-08-29T03:40:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/biocina-gpn-vaccine-development/ 2023-11-06T10:02:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/innovators-deuterated-drug-synthesis-pharmaceutical/ 2024-08-29T04:26:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/innovators-cell-gene-therapy-corneal-endothelial-cell-culturing-pharmaceutical/ 2024-07-30T07:51:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/innovators-cell-immunomodulation-pharmaceutical/ 2024-08-29T05:01:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/innovators-cancer-combination-therapy-pharmaceutical/ 2024-08-29T03:43:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/innovators-cell-gene-therapy-chimeric-antigen-receptors-pharmaceutical/ 2024-07-29T07:28:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/innovators-anti-rsv-vaccines-pharmaceutical/ 2024-08-29T05:06:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/innovators-cell-gene-therapy-car-t-cell-based-therapies-pharmaceutical/ 2024-07-31T07:09:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/innovators-anti-il-monoclonal-antibodies-pharmaceutical/ 2024-08-29T03:47:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/innovators-cell-gene-therapy-cancer-car-t-receptors-pharmaceutical/ 2024-07-30T11:26:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/innovators-antibody-drug-conjugates-pharmaceutical/ 2024-08-29T03:47:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/innovators-antibody-encoding-polynucleotide-libraries-pharmaceutical/ 2024-08-29T05:04:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/starton-cancels-healthwell-merger/ 2023-11-06T08:48:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/innovators-ai-drug-repurposing-ai-pharmaceutical/ 2024-07-29T05:35:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/innovators-amyloid-precursor-targeted-therapies-pharmaceutical/ 2024-08-29T05:05:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/medtechs-covid-boom-is-well-and-truly-over-as-avail-olive-shutter/ 2023-11-03T18:56:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/innovators-ai-ai-in-multiomics-pharmaceutical/ 2024-07-29T05:46:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/hungary-serbia-to-increase-chinese-fdi/ 2023-11-05T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/saab-to-build-missile-factory-india-investment/ 2023-11-05T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/alto-100-alto-neuroscience-post-traumatic-stress-disorder-ptsd-likelihood-of-approval/ 2025-01-21T16:53:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgb-16673-beigene-waldenstrom-macroglobulinemia-lymphoplasmacytic-lymphoma-likelihood-of-approval-2/ 2024-12-25T17:39:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgb-16673-beigene-marginal-zone-b-cell-lymphoma-likelihood-of-approval-2/ 2024-12-25T17:39:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgb-16673-beigene-mantle-cell-lymphoma-likelihood-of-approval-2/ 2024-12-25T17:39:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ivxa-12-icosavax-human-metapneumovirus-infections-likelihood-of-approval-2/ 2025-01-19T18:04:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vyznova-aurion-biotechnologies-corneal-edema-likelihood-of-approval-2/ 2024-12-25T17:36:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/okyo-0101-okyo-pharma-keratoconjunctivitis-sicca-dry-eye-likelihood-of-approval-2/ 2024-12-25T17:34:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mibavademab-regeneron-pharmaceuticals-congenital-generalized-lipodystrophy-berardinelli-seip-syndrome-likelihood-of-approval-2/ 2024-12-25T17:33:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mibavademab-regeneron-pharmaceuticals-acquired-generalized-lipodystrophy-lawrence-syndrome-likelihood-of-approval-2/ 2024-12-25T17:33:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fp-045-foresee-pharmaceuticals-fanconi-anemia-likelihood-of-approval-2/ 2024-12-25T17:27:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/arct-810-arcturus-therapeutics-ornithine-transcarbamylase-deficiency-likelihood-of-approval-2/ 2024-12-25T17:27:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/osimertinib-mesylate-astrazeneca-non-small-cell-lung-carcinoma-likelihood-of-approval-2/ 2024-12-25T17:25:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/imm-124e-immuron-traveler-s-diarrhea-likelihood-of-approval-2/ 2025-01-19T17:41:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/apatinib-mesylate-elevar-therapeutics-synovial-sarcoma-likelihood-of-approval-2/ 2024-12-25T17:21:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/apatinib-mesylate-elevar-therapeutics-melanoma-likelihood-of-approval-2/ 2024-12-25T17:21:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/methotrexate-aldeyra-therapeutics-retinitis-pigmentosa-retinitis-likelihood-of-approval-2/ 2025-01-19T17:17:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ivxa-12-icosavax-respiratory-syncytial-virus-rsv-infections-likelihood-of-approval-2/ 2025-01-19T16:59:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mrt-2359-monte-rosa-therapeutics-small-cell-lung-cancer-likelihood-of-approval/ 2024-06-14T01:33:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/clenbuterol-hydrochloride-curasen-therapeutics-parkinson-s-disease-likelihood-of-approval-2/ 2025-01-19T16:55:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/al-001-alzamend-neuro-alzheimer-s-disease-likelihood-of-approval-2/ 2025-01-19T16:54:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vorolanib-eyepoint-pharmaceuticals-wet-neovascular-exudative-macular-degeneration-likelihood-of-approval-2/ 2024-12-25T17:04:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/talditercept-alfa-biohaven-spinal-muscular-atrophy-sma-likelihood-of-approval-2/ 2024-12-25T17:03:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/letermovir-merck-human-immunodeficiency-virus-hiv-infections-aids-likelihood-of-approval-2/ 2024-12-25T17:03:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rimegepant-sulfate-odt-pfizer-psoriasis-likelihood-of-approval-2/ 2024-09-09T01:40:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nemolizumab-galderma-atopic-dermatitis-atopic-eczema-likelihood-of-approval/ 2025-01-21T16:58:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/seliciclib-cyclacel-pharmaceuticals-rheumatoid-arthritis-likelihood-of-approval-2/ 2025-01-19T16:40:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/apatinib-mesylate-elevar-therapeutics-leiomyosarcoma-likelihood-of-approval-2/ 2024-12-25T16:58:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bidridistrogene-xeboparvovec-sarepta-therapeutics-net-present-value/ 2024-06-13T18:46:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zanidatamab-jazz-pharmaceuticals-net-present-value/ 2024-07-02T02:02:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atacicept-vera-therapeutics-net-present-value/ 2024-07-02T02:05:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mbx-1416-mbx-biosciences-inc-hypoglycemia-likelihood-of-approval/ 2024-04-19T17:41:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rpa-601-rocket-pharmaceuticals-cardiomyopathy-likelihood-of-approval/ 2024-07-05T06:36:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sor-102-sorriso-pharmaceuticals-ulcerative-colitis-likelihood-of-approval/ 2023-11-06T21:53:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/denosumab-biosimilar-alvotech-autoimmune-disorders-likelihood-of-approval/ 2025-01-20T16:23:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atb-1651-amtixbio-onychomycosis-tinea-unguium-likelihood-of-approval/ 2023-11-06T21:46:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gs-0272-gilead-sciences-rheumatoid-arthritis-likelihood-of-approval/ 2025-01-20T16:22:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sir-9900-sironax-neurodegenerative-diseases-likelihood-of-approval/ 2025-01-20T16:22:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sir-9900-sironax-inflammation-likelihood-of-approval/ 2025-01-20T16:22:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/emb-09-epimab-biotherapeutics-endometrial-cancer-likelihood-of-approval/ 2025-01-20T16:22:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kt-333-kymera-therapeutics-peripheral-t-cell-lymphomas-ptcl-likelihood-of-approval/ 2025-01-20T16:22:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kt-333-kymera-therapeutics-cutaneous-t-cell-lymphoma-likelihood-of-approval/ 2025-01-20T16:22:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ko-2806-kura-oncology-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2025-01-20T16:22:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ml-007-maplight-therapeutics-alzheimer-s-disease-likelihood-of-approval/ 2025-01-20T16:22:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jnj-2113-johnson-johnson-ulcerative-colitis-likelihood-of-approval/ 2025-01-20T16:22:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ab-001-agastiya-biotech-liver-cancer-likelihood-of-approval/ 2025-01-20T16:22:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ab-001-agastiya-biotech-colon-cancer-likelihood-of-approval/ 2025-01-20T16:22:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ab-001-agastiya-biotech-breast-cancer-likelihood-of-approval/ 2025-01-20T16:22:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rbd-4059-suzhou-ribo-life-sciences-thromboembolism-likelihood-of-approval/ 2025-01-20T16:22:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/uncategorized/polzastobart-concentra-biosciences-head-and-neck-cancer-squamous-cell-carcinoma-likelihood-of-approval/ 2023-11-04T05:50:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/polzastobart-concentra-biosciences-extrahepatic-bile-duct-cancer-likelihood-of-approval/ 2024-07-05T18:20:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ff-10158-advanced-accelerator-applications-adenocarcinoma-of-the-gastroesophageal-junction-likelihood-of-approval/ 2025-01-20T16:21:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ff-10158-advanced-accelerator-applications-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2025-01-20T16:21:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cst-101-curasen-therapeutics-parkinson-s-disease-likelihood-of-approval/ 2024-02-08T04:14:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vron-0200-virion-therapeutics-hepatitis-b-likelihood-of-approval/ 2024-05-20T03:34:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tinengotinib-transthera-sciences-nanjing-hepatocellular-carcinoma-likelihood-of-approval/ 2025-01-20T16:21:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bms-986446-bristol-myers-squibb-alzheimer-s-disease-likelihood-of-approval/ 2025-01-20T16:21:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/csl-040-csl-transplant-rejection-likelihood-of-approval/ 2025-01-20T16:21:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hymecromone-halo-biosciences-pulmonary-hypertension-likelihood-of-approval/ 2025-01-20T16:21:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ifinatamab-deruxtecan-daiichi-sankyo-esophageal-squamous-cell-carcinoma-escc-likelihood-of-approval/ 2025-01-20T16:21:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lorundrostat-hydrobromide-mineralys-therapeutics-resistant-hypertension-likelihood-of-approval/ 2024-02-08T04:13:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lorundrostat-hydrobromide-mineralys-therapeutics-chronic-kidney-disease-chronic-renal-failure-likelihood-of-approval/ 2024-02-08T04:13:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ezabenlimab-boehringer-ingelheim-international-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2025-01-20T16:21:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zastaprazan-onconic-therapeutics-corrosive-esophagitis-erosive-esophagitis-likelihood-of-approval/ 2025-01-20T16:21:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bnt-211-biontech-testicular-cancer-likelihood-of-approval/ 2024-07-05T06:31:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aspacytarabine-hydrochloride-ayala-pharmaceuticals-myelodysplastic-syndrome-likelihood-of-approval/ 2025-01-20T16:20:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pep-010-pep-therapy-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2025-01-20T16:20:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lulizumab-pegol-bristol-myers-squibb-kidney-transplant-rejection-likelihood-of-approval/ 2023-11-06T17:35:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/feladilimab-gsk-oral-cavity-mouth-cancer-likelihood-of-approval/ 2025-01-20T16:20:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/feladilimab-gsk-oropharyngeal-cancer-likelihood-of-approval/ 2025-01-20T16:20:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/feladilimab-gsk-laryngeal-cancer-likelihood-of-approval/ 2025-01-20T16:20:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/feladilimab-gsk-hypopharyngeal-cancer-likelihood-of-approval/ 2025-01-20T16:20:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anx-005-annexon-guillain-barre-syndrome-likelihood-of-approval/ 2025-01-20T16:20:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/etrasimod-pfizer-crohn-s-disease-regional-enteritis-likelihood-of-approval/ 2025-01-20T16:20:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/eniluracil-processa-pharmaceuticals-pancreatic-cancer-likelihood-of-approval/ 2025-01-20T16:20:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ph-15-vistagen-therapeutics-cognitive-impairment-likelihood-of-approval/ 2025-01-20T16:20:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/defactinib-hydrochloride-verastem-peritoneal-cancer-likelihood-of-approval/ 2025-01-20T16:20:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/defactinib-hydrochloride-verastem-fallopian-tube-cancer-likelihood-of-approval/ 2025-01-20T16:20:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aflibercept-regeneron-pharmaceuticals-retinopathy-likelihood-of-approval/ 2025-01-20T16:20:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/balixafortide-spexis-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2025-01-20T16:19:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vonoprazan-fumarate-phathom-pharmaceuticals-reflux-esophagitis-gastroesophageal-reflux-disease-likelihood-of-approval/ 2025-01-20T16:19:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/disc-0974-disc-medicine-net-present-value/ 2024-06-13T18:47:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mebufotenin-gh-research-net-present-value/ 2024-05-16T02:08:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ide-397-ideaya-biosciences-net-present-value/ 2024-05-16T02:09:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sevasemten-edgewise-therapeutics-net-present-value/ 2024-05-16T02:09:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/uncategorized/parsaclisib-incyte-net-present-value/ 2023-11-04T02:41:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/pierre-fabre-and-atara-expand-licensing-agreement-for-epstein-barr-therapy/ 2023-11-03T15:44:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/kronos-downsizes-workforce-by-19-to-funnel-funds-into-cancer-drugs/ 2023-11-03T15:02:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/glp1r-targeting-drugs-type-2-diabetes/ 2023-11-03T14:35:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/phathom-scores-two-fda-wins-for-acid-reflux-drug-after-several-setbacks/ 2023-11-03T14:26:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/the-hot-new-tech-transforming-pharmaceuticals-modular-real-time-communication/ 2023-11-03T15:50:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/terremoto-secures-175m-in-series-b-to-advance-small-molecule-drugs/ 2023-11-03T13:53:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/poland-reimbursement-act-disappointing-but-not-disastrous/ 2023-11-06T09:18:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/expanded-use-of-oral-blood-thinners-by-nhs-has-saved-thousands-of-lives/ 2023-11-03T13:05:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/eli-lilly-loss-q3-2023/ 2023-11-03T10:32:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/i-mab-hi-bio-breakthrough-pmn/ 2023-11-03T10:20:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ec-gedeon-richter-sumitomo-ryeqo/ 2023-11-03T09:11:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/bayer-broad-institute-therapies-development/ 2023-11-03T08:51:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/china-direct-investment-liabilities-q3/ 2023-11-02T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/report-saudis-eyeing-up-5bn-ipl-investment/ 2023-11-02T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/poland-to-launch-investment-fund-ukraine-fdi/ 2023-11-02T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/dbsa-black-rock-graphite-project/ 2023-11-02T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/sangamo-tightens-the-belt-cutting-staff-and-assets-to-advance-product-pipeline/ 2023-11-02T19:12:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/moderna-posts-reported-net-loss-of-3-6bn-in-q3-earnings/ 2023-11-02T16:01:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/prelude-and-abcellera-jump-on-the-adc-train-with-partnership/ 2023-11-02T14:01:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/rani-cuts-workforce-by-25-and-reprioritises-drug-pipeline/ 2023-11-02T12:49:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/excellence-awards/excellence-awards-guide/ 2025-06-09T06:51:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/memo-therapeutics-raises-27-67m-for-kidney-transplant-infection-trial/ 2023-11-02T11:52:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/scaling-up-rna-lnps-clinical-manufacturing-strategies/ 2023-11-02T13:28:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/gsk-operating-profit-q3-2023/ 2023-11-02T10:49:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/generatebiomedicines-oncology-cell-therapies/ 2023-11-15T17:41:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/aldeyra-abbvie-partner-reproxalap/ 2023-11-02T09:20:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/mhra-authorises-pfizer-litfulo/ 2023-11-02T09:21:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/kosovo-fdi-january-august-2023-increase/ 2023-11-01T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/pakistan-us-call-for-fdi-increase/ 2023-11-01T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/amgen-scores-fda-approval-for-stelara-biosimilar/ 2023-11-01T17:18:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/onl-therapeutics-seeks-upto-100m-to-further-eye-disease-pipeline/ 2023-11-01T17:15:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/astrazeneca-and-cellectis-partner-to-advance-cell-and-gene-therapies/ 2023-11-15T17:42:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/astrazeneca-and-cellectis-partner-to-advance-cell-and-gene-therapies-2/ 2024-03-20T03:34:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/abcam-deal-likely-to-close-as-founder-suspends-bid-to-block-takeover/ 2023-11-01T17:34:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/curavit-launches-heor-services-for-digital-therapeutic-trials/ 2023-11-01T12:35:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/uk-seizes-illegally-traded-medicines-and-devices-worth-over-84m/ 2023-11-01T13:27:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/kite-epic-bio-cancer-cell-therapies/ 2023-11-15T17:41:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/pfizer-net-loss-q3-2023/ 2023-11-01T10:53:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-novartis-cosentyx/ 2023-11-01T08:49:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/gsk-arrowhead-deal-jnj-3989/ 2023-11-01T09:03:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/shorla-acquires-methotrexate-solution-from-therakind-in-the-us/ 2023-10-31T16:24:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/ma-market-performance-suffered-in-q3-2023/ 2023-10-31T16:18:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/aragen-invests-30m-in-new-biologics-manufacturing-facility-in-india/ 2023-10-31T14:48:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/sellas-presses-ahead-with-fast-track-designation-for-lymphoma/ 2023-11-27T21:31:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/half-of-top-20-biopharma-ira-q3-2023/ 2023-10-31T13:51:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/sosei-heptares-hits-discovery-milestone-in-gpcr-deal-with-genentech/ 2023-10-31T11:37:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/roche-seeks-label-expansion-for-elevidys-amid-missing-phase-iii-endpoint/ 2023-10-31T13:35:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/arrivent-lung-cancer-therapy/ 2023-10-31T10:38:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-day-one-nda-tovorafenib/ 2023-10-31T10:10:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/anheart-nippon-kayaku-licence-deal/ 2023-10-31T08:28:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/vect-horus-novo-nordisk-therapeutics-development/ 2023-10-31T08:26:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/interviews/qa-uk-pharma-manufacturing-prepares-for-imminent-shake-up-in-2024/ 2023-11-17T12:16:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/ma-market-performance-suffered-in-q3-2023-2/ 2023-10-30T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/allyx-sets-phase-ii-plans-in-motion-after-phase-ia-results-for-alzheimers-drug/ 2023-10-30T18:05:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/rishi-sunak-addresses-existential-ai-threats-ahead-of-uk-safety-summit/ 2023-10-30T17:21:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ai-skills-can-increase-worker-salary-as-much-as-40-says-study/ 2023-10-30T17:14:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/signal-uk-biobank-raises-32m-in-funding-via-public-private-partnership/ 2023-10-30T17:27:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ema-validates-bms-opdivo-application-for-bladder-cancer/ 2023-10-30T17:00:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/coherus-and-junshis-pd-1-inhibitor-approved-for-nasopharyngeal-carcinoma/ 2023-10-30T16:48:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ema-dismisses-thyroid-cancer-link-with-anti-obesity-glp-1-receptor-agonists/ 2023-10-30T15:32:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/intas-licenses-helnius-antibody-for-marketing-in-europe-and-india/ 2023-10-30T12:49:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/merck-partners-with-hengrui-in-deal-worth-up-to-1-48bn/ 2023-10-30T11:41:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/abbvie-q3-2023-net-earnings/ 2023-10-30T10:23:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ema-immunogen-ovarian-cancer-therapy/ 2023-10-30T10:35:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/will-mobile-visits-help-the-clinical-trials-industry-meet-its-diversity-goals/ 2025-09-22T12:26:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-eye-drops-infection-risk/ 2023-10-30T08:48:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/uk-ai-drug-development/ 2023-10-30T09:10:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgb-10188-beigene-epithelial-ovarian-cancer-likelihood-of-approval-2/ 2024-12-25T18:25:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgb-10188-beigene-peritoneal-cancer-likelihood-of-approval-2/ 2024-12-25T18:24:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgb-10188-beigene-fallopian-tube-cancer-likelihood-of-approval-2/ 2024-12-25T18:24:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/osemitamab-transcenta-metastatic-biliary-tract-cancer-likelihood-of-approval-2/ 2025-01-20T02:16:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/yh-25724-boehringer-ingelheim-international-obesity-likelihood-of-approval-2/ 2024-12-25T18:13:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vg-161-virogin-biotech-metastatic-hepatocellular-carcinoma-hcc-likelihood-of-approval-2/ 2024-12-25T18:13:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cemiplimab-regeneron-pharmaceuticals-merkel-cell-carcinoma-likelihood-of-approval-2/ 2024-12-25T18:12:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/livmoniplimab-abbvie-metastatic-hepatocellular-carcinoma-hcc-likelihood-of-approval-3/ 2024-12-25T18:12:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azeliragon-cantex-pharmaceuticals-refractory-brain-metastasis-likelihood-of-approval-2/ 2024-12-25T18:10:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nx-5948-nurix-therapeutics-waldenstrom-macroglobulinemia-lymphoplasmacytic-lymphoma-likelihood-of-approval-2/ 2024-12-25T18:09:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nx-5948-nurix-therapeutics-marginal-zone-b-cell-lymphoma-likelihood-of-approval-2/ 2024-12-25T18:09:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nx-5948-nurix-therapeutics-mantle-cell-lymphoma-likelihood-of-approval-2/ 2024-12-25T18:08:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nx-5948-nurix-therapeutics-follicular-lymphoma-likelihood-of-approval-2/ 2024-12-25T18:08:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trastuzumab-rezetecan-jiangsu-hengrui-medicine-human-epidermal-growth-factor-receptor-2-positive-breast-cancer-her2-breast-cancer-likelihood-of-approval-2/ 2024-12-25T18:08:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nx-5948-nurix-therapeutics-diffuse-large-b-cell-lymphoma-likelihood-of-approval-2/ 2024-12-25T18:08:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trastuzumab-rezetecan-jiangsu-hengrui-medicine-adenocarcinoma-of-the-gastroesophageal-junction-likelihood-of-approval-2/ 2024-12-25T18:08:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trastuzumab-rezetecan-jiangsu-hengrui-medicine-gastric-cancer-likelihood-of-approval-2/ 2024-12-25T18:08:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ezabenlimab-boehringer-ingelheim-international-gastric-cancer-likelihood-of-approval-2/ 2024-12-25T18:08:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lisaftoclax-ascentage-pharma-group-international-chronic-lymphocytic-leukemia-cll-likelihood-of-approval-2/ 2024-12-25T18:08:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bintrafusp-alfa-merck-bladder-cancer-likelihood-of-approval-2/ 2024-12-25T18:07:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aldesleukin-iltoo-pharma-bipolar-disorder-manic-depression-likelihood-of-approval-2/ 2024-12-25T18:07:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gotistobart-biontech-net-present-value/ 2024-12-13T02:53:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ceralasertib-astrazeneca-net-present-value/ 2024-07-02T02:11:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/imdusiran-sodium-arbutus-biopharma-net-present-value/ 2024-06-13T18:54:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/plozasiran-sodium-arrowhead-pharmaceuticals-net-present-value/ 2024-12-13T02:51:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/masofaniten-essa-pharma-net-present-value/ 2024-04-16T17:04:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rifaximin-alfasigma-collagenous-colitis-likelihood-of-approval-2/ 2024-12-25T18:07:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/belinostat-acrotech-biopharma-diffuse-large-b-cell-lymphoma-likelihood-of-approval-2/ 2024-12-25T18:07:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mil-62-beijing-mabworks-biotech-chronic-lymphocytic-leukemia-cll-likelihood-of-approval-2/ 2024-12-25T18:06:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hrs-5965-jiangsu-hengrui-medicine-iga-nephropathy-berger-s-disease-likelihood-of-approval-2/ 2024-12-25T18:05:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/my-008-createrna-science-and-technology-iga-nephropathy-berger-s-disease-likelihood-of-approval-2/ 2024-09-09T02:26:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/uncategorized/nmdp-02-nmd-pharma-spinal-muscular-atrophy-sma-likelihood-of-approval/ 2023-10-28T03:07:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vusolimogene-oderparepvec-replimune-merkel-cell-carcinoma-likelihood-of-approval-2/ 2024-12-25T17:28:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/psilocybin-compass-pathways-body-dysmorphic-disorder-likelihood-of-approval/ 2025-01-19T18:26:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hmbd-001-hummingbird-bioscience-pancreatic-ductal-adenocarcinoma-likelihood-of-approval-2/ 2024-12-25T18:04:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zastaprazan-onconic-therapeutics-gastric-ulcers-likelihood-of-approval-2/ 2024-12-25T18:04:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/milvexian-bristol-myers-squibb-venous-thromboembolism-likelihood-of-approval-2/ 2024-12-25T17:28:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/olezarsen-sodium-ionis-pharmaceuticals-familial-chylomicronemia-type-i-hyperlipoproteinemia-likelihood-of-approval/ 2024-06-14T03:58:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/com-902-compugen-peritoneal-cancer-likelihood-of-approval/ 2024-09-09T02:24:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/com-902-compugen-epithelial-ovarian-cancer-likelihood-of-approval/ 2024-09-09T02:24:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/com-902-compugen-fallopian-tube-cancer-likelihood-of-approval/ 2024-09-09T02:24:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/com-902-compugen-metastatic-colorectal-cancer-likelihood-of-approval/ 2024-09-09T02:24:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/com-902-compugen-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-09-09T02:24:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/spesolimab-boehringer-ingelheim-international-netherton-syndrome-trichorrhexis-invaginata-bamboo-hair-likelihood-of-approval-2/ 2024-12-25T17:27:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bintrafusp-alfa-merck-metastatic-colorectal-cancer-likelihood-of-approval-2/ 2024-12-25T17:27:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/iberdomide-hydrochloride-bristol-myers-squibb-refractory-multiple-myeloma-likelihood-of-approval-2/ 2024-12-25T18:04:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gedeptin-geovax-labs-salivary-gland-cancer-likelihood-of-approval/ 2025-01-19T18:25:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/iberdomide-hydrochloride-bristol-myers-squibb-relapsed-multiple-myeloma-likelihood-of-approval-2/ 2024-12-25T18:04:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cetuximab-biobetter-shanghai-henlius-biotech-nasopharyngeal-cancer-likelihood-of-approval-2/ 2024-12-25T17:27:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/onabotulinumtoxin-a-abbvie-myofascial-pain-syndrome-chronic-myofascial-pain-likelihood-of-approval-2/ 2024-12-25T18:03:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tucidinostat-huya-bioscience-international-anaplastic-large-cell-lymphoma-alcl-likelihood-of-approval-2/ 2024-12-25T18:03:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vemurafenib-f-hoffmann-la-roche-craniopharyngioma-likelihood-of-approval-2/ 2024-12-25T18:03:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bexotegrast-pliant-therapeutics-liver-fibrosis-likelihood-of-approval-2/ 2024-12-25T18:03:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azacitidine-bristol-myers-squibb-pancreatic-ductal-adenocarcinoma-likelihood-of-approval-2/ 2024-12-25T18:03:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tinostamustine-mundipharma-edo-t-cell-leukemia-likelihood-of-approval-2/ 2024-12-25T17:58:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nipocalimab-johnson-johnson-erythroblastosis-fetalis-hemolytic-disease-in-newborns-likelihood-of-approval-2/ 2024-12-25T17:27:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cemiplimab-regeneron-pharmaceuticals-hormone-sensitive-prostate-cancer-likelihood-of-approval-2/ 2024-12-25T17:27:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cemiplimab-regeneron-pharmaceuticals-oropharyngeal-cancer-likelihood-of-approval-2/ 2024-12-25T17:27:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/odronextamab-regeneron-pharmaceuticals-marginal-zone-b-cell-lymphoma-likelihood-of-approval-2/ 2024-12-25T17:26:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/odronextamab-regeneron-pharmaceuticals-b-cell-non-hodgkin-lymphoma-likelihood-of-approval-2/ 2024-12-25T17:26:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cemiplimab-regeneron-pharmaceuticals-t-cell-lymphomas-likelihood-of-approval-2/ 2024-12-25T17:56:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cemiplimab-regeneron-pharmaceuticals-natural-killer-cell-lymphomas-likelihood-of-approval-2/ 2024-12-25T17:56:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rademikibart-suzhou-connect-biopharmaceuticals-asthma-likelihood-of-approval-2/ 2024-12-25T17:56:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pegcetacoplan-apellis-pharmaceuticals-membranoproliferative-glomerulonephritis-mesangiocapillary-glomerulonephritis-likelihood-of-approval-2/ 2024-12-25T17:26:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/paxalisib-kazia-therapeutics-leptomeningeal-disease-neoplastic-meningitis-leptomeningeal-carcinomatosis-likelihood-of-approval-2/ 2024-12-25T17:55:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anselamimab-astrazeneca-net-present-value/ 2024-07-02T02:09:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/siremadlin-succinate-novartis-secondary-acute-myeloid-leukemia-likelihood-of-approval/ 2024-09-09T05:59:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/psilocybin-ceruvia-lifesciences-smoking-cessation-likelihood-of-approval-2/ 2024-12-25T17:26:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/onl-1204-onl-therapeutics-retinal-pigment-epithelial-rpe-detachment-likelihood-of-approval-2/ 2024-12-25T17:26:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/elacestrant-hydrochloride-stemline-therapeutics-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2025-01-19T18:20:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sirolimus-palvella-therapeutics-lymphoproliferative-disorders-likelihood-of-approval/ 2025-01-19T17:44:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/oncolytic-virus-for-human-papillomavirus-associated-cancer-human-papillomavirus-infections-and-coronavirus-disease-2019-covid-19-blue-sky-immunotherapies-cervical-intraepithelial-neoplasia-cin-likel-2/ 2025-01-19T18:20:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mb-106-mustang-bio-marginal-zone-b-cell-lymphoma-likelihood-of-approval-2/ 2024-12-25T17:53:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/oncolytic-virus-for-human-papillomavirus-associated-cancer-human-papillomavirus-infections-and-coronavirus-disease-2019-covid-19-blue-sky-immunotherapies-human-papillomavirus-infections-likelihood-o-2/ 2025-01-19T18:19:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/camlipixant-gsk-chronic-cough-likelihood-of-approval-2/ 2024-12-25T17:53:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/irl-201104-revolo-biotherapeutics-acute-respiratory-distress-syndrome-likelihood-of-approval-2/ 2024-12-25T17:53:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/irl-201104-revolo-biotherapeutics-seasonal-allergic-rhinitis-likelihood-of-approval-2/ 2024-12-25T17:25:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/irl-201104-revolo-biotherapeutics-allergies-likelihood-of-approval-2/ 2024-12-25T17:25:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/octreotide-la-camurus-neuroendocrine-tumors-likelihood-of-approval-2/ 2024-12-25T17:53:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rituximab-biogen-post-transplant-lymphoproliferative-disorder-likelihood-of-approval-2/ 2024-12-25T17:23:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rituximab-f-hoffmann-la-roche-marginal-zone-b-cell-lymphoma-likelihood-of-approval-2/ 2024-12-25T17:23:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/poly-iclc-oncovir-prostate-cancer-likelihood-of-approval-2/ 2024-12-25T17:25:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fibromun-philogen-malignant-glioma-likelihood-of-approval-2/ 2024-12-25T17:53:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fibromun-philogen-glioblastoma-multiforme-gbm-likelihood-of-approval-2/ 2024-12-25T17:53:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgba-445-beigene-nasopharyngeal-cancer-likelihood-of-approval-2/ 2024-12-25T17:50:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/navtemadlin-kartos-therapeutics-refractory-acute-myeloid-leukemia-likelihood-of-approval-2/ 2024-12-25T17:25:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/thn-391-therini-bio-alzheimer-s-disease-likelihood-of-approval-2/ 2024-12-25T17:49:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/k-757-kallyope-obesity-likelihood-of-approval-2/ 2024-12-25T17:48:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tisagenlecleucel-novartis-primary-mediastinal-b-cell-lymphoma-likelihood-of-approval-2/ 2024-12-25T17:22:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/agen-2373-agenus-castration-resistant-prostate-cancer-crpc-likelihood-of-approval-2/ 2024-12-25T17:47:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/selinexor-karyopharm-therapeutics-peripheral-nerve-sheath-tumor-neurofibrosarcoma-likelihood-of-approval-2/ 2024-12-25T17:24:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vusolimogene-oderparepvec-replimune-melanoma-likelihood-of-approval-2/ 2024-12-25T17:47:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/radspherin-oncoinvent-epithelial-ovarian-cancer-likelihood-of-approval-2/ 2024-12-25T17:46:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/radspherin-oncoinvent-fallopian-tube-cancer-likelihood-of-approval-2/ 2024-12-25T17:46:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cemiplimab-regeneron-pharmaceuticals-metastatic-pancreatic-cancer-likelihood-of-approval-2/ 2024-12-25T17:46:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/irinotecan-hydrochloride-ipsen-epithelial-ovarian-cancer-likelihood-of-approval-2/ 2024-12-25T17:21:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pelareorep-oncolytics-biotech-pancreatic-ductal-adenocarcinoma-likelihood-of-approval-2/ 2024-12-25T17:21:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ramucirumab-eli-lilly-and-co-thymic-carcinoma-likelihood-of-approval-2/ 2024-12-25T17:21:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lifirafenib-maleate-beigene-non-small-cell-lung-cancer-likelihood-of-approval-2/ 2024-12-25T17:45:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rifamycin-sodium-cr-cosmo-pharmaceuticals-hepatic-encephalopathy-likelihood-of-approval-2/ 2024-12-25T17:20:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/paclitaxel-dae-hwa-pharmaceutical-metastatic-breast-cancer-likelihood-of-approval-2/ 2024-12-25T17:45:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lifirafenib-maleate-beigene-ovarian-cancer-likelihood-of-approval-2/ 2024-12-25T17:45:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/alimta-eli-lilly-and-co-chordoma-likelihood-of-approval-2/ 2024-09-09T01:54:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/axicabtagene-ciloleucel-gilead-sciences-refractory-acute-myeloid-leukemia-likelihood-of-approval-2/ 2024-12-25T17:44:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/axicabtagene-ciloleucel-gilead-sciences-burkitt-lymphoma-likelihood-of-approval-2/ 2024-12-25T17:44:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/axicabtagene-ciloleucel-gilead-sciences-refractory-chronic-lymphocytic-leukemia-cll-likelihood-of-approval-2/ 2024-12-25T17:44:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/isatuximab-sanofi-natural-killer-cell-lymphomas-likelihood-of-approval-2/ 2024-12-25T17:20:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/axicabtagene-ciloleucel-gilead-sciences-acute-myelocytic-leukemia-aml-acute-myeloblastic-leukemia-likelihood-of-approval-2/ 2024-12-25T17:44:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/axicabtagene-ciloleucel-gilead-sciences-chronic-lymphocytic-leukemia-cll-likelihood-of-approval-2/ 2024-12-25T17:44:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/isatuximab-sanofi-acute-myelocytic-leukemia-aml-acute-myeloblastic-leukemia-likelihood-of-approval-2/ 2024-12-25T17:20:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/denifanstat-sagimet-biosciences-glioblastoma-multiforme-gbm-likelihood-of-approval-2/ 2024-12-25T17:44:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/axicabtagene-ciloleucel-gilead-sciences-acute-lymphocytic-leukemia-all-acute-lymphoblastic-leukemia-likelihood-of-approval-2/ 2024-12-25T17:44:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/itolizumab-equillium-systemic-lupus-erythematosus-likelihood-of-approval-2/ 2024-12-25T17:20:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/secukinumab-novartis-congenital-ichthyosis-likelihood-of-approval/ 2024-05-20T01:58:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/secukinumab-novartis-polymyalgia-rheumatica-pmr-likelihood-of-approval/ 2024-04-19T01:14:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/secukinumab-novartis-netherton-syndrome-trichorrhexis-invaginata-bamboo-hair-likelihood-of-approval/ 2024-04-19T01:14:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cobimetinib-fumarate-f-hoffmann-la-roche-craniopharyngioma-likelihood-of-approval-2/ 2024-12-25T17:20:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cobimetinib-fumarate-f-hoffmann-la-roche-relapsed-acute-myeloid-leukemia-likelihood-of-approval-2/ 2024-12-25T17:19:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cobimetinib-fumarate-f-hoffmann-la-roche-refractory-acute-myeloid-leukemia-likelihood-of-approval-2/ 2024-12-25T17:19:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/shj-002-sunhawk-vision-biotech-keratoconjunctivitis-sicca-dry-eye-likelihood-of-approval-2/ 2025-01-19T17:21:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/resminostat-4sc-mycosis-fungoides-likelihood-of-approval-2/ 2024-12-25T17:43:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/denosumab-biosimilar-celltrion-post-menopausal-osteoporosis-likelihood-of-approval/ 2025-01-19T17:21:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/resminostat-4sc-sezary-syndrome-likelihood-of-approval-2/ 2024-12-25T17:43:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nkx-019-nkarta-marginal-zone-b-cell-lymphoma-likelihood-of-approval-2/ 2024-12-25T17:42:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ibrutinib-abbvie-primary-cns-lymphoma-likelihood-of-approval-2/ 2024-12-25T17:18:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nkx-019-nkarta-refractory-chronic-lymphocytic-leukemia-cll-likelihood-of-approval-2/ 2024-12-25T17:42:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nkx-019-nkarta-relapsed-chronic-lymphocytic-leukemia-cll-likelihood-of-approval-2/ 2024-12-25T17:42:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nkx-019-nkarta-follicular-lymphoma-likelihood-of-approval-2/ 2024-12-25T17:42:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nkx-019-nkarta-waldenstrom-macroglobulinemia-lymphoplasmacytic-lymphoma-likelihood-of-approval-2/ 2024-12-25T17:42:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nkx-019-nkarta-diffuse-large-b-cell-lymphoma-likelihood-of-approval-2/ 2024-12-25T17:42:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nkx-019-nkarta-mantle-cell-lymphoma-likelihood-of-approval-2/ 2024-12-25T17:42:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/imetelstat-sodium-geron-relapsed-acute-myeloid-leukemia-likelihood-of-approval-2/ 2024-12-25T17:42:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trametinib-dimethyl-sulfoxide-novartis-high-grade-glioma-likelihood-of-approval-2/ 2024-12-25T17:42:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/imetelstat-sodium-geron-refractory-acute-myeloid-leukemia-likelihood-of-approval-2/ 2024-12-25T17:42:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/uncategorized/tac-100-triumvira-immunologics-gastroesophageal-ge-junction-carcinomas-likelihood-of-approval-2/ 2023-10-28T00:27:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fibromun-philogen-melanoma-likelihood-of-approval-2/ 2024-12-25T17:41:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vtx-2735-ventyx-biosciences-familial-cold-autoinflammatory-syndrome-familial-cold-urticaria-likelihood-of-approval-2/ 2024-12-25T17:38:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mbf-015-medibiofarma-huntington-disease-likelihood-of-approval-2/ 2024-12-25T17:38:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tqb-2618-chia-tai-tianqing-pharmaceutical-group-nasopharyngeal-cancer-likelihood-of-approval-2/ 2024-12-25T17:37:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/onureg-bristol-myers-squibb-relapsed-acute-myeloid-leukemia-likelihood-of-approval-2/ 2024-12-25T17:37:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/onureg-bristol-myers-squibb-refractory-acute-myeloid-leukemia-likelihood-of-approval-2/ 2024-12-25T17:36:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/amitriptyline-hydrochloride-algotherapeutix-erythromelalgia-likelihood-of-approval-2/ 2024-12-25T17:36:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/disc-0974-disc-medicine-anemia-in-chronic-kidney-disease-renal-anemia-likelihood-of-approval-2/ 2024-12-25T17:35:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nkx-019-nkarta-b-cell-chronic-lymphocytic-leukemia-likelihood-of-approval-2/ 2024-12-25T17:35:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ensomafusp-alfa-f-hoffmann-la-roche-follicular-lymphoma-likelihood-of-approval-2/ 2024-12-25T17:35:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/impt-314-immpact-bio-usa-primary-mediastinal-b-cell-lymphoma-likelihood-of-approval-2/ 2024-12-25T17:35:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/impt-314-immpact-bio-usa-refractory-chronic-lymphocytic-leukemia-cll-likelihood-of-approval-2/ 2024-12-25T17:35:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azd-0780-astrazeneca-cardiovascular-disease-likelihood-of-approval-2/ 2024-12-25T17:35:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cbx-12-cybrexa-small-cell-lung-cancer-likelihood-of-approval-2/ 2024-12-25T17:35:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ab-1005-asklepios-biopharmaceutical-parkinson-s-disease-likelihood-of-approval-2/ 2024-12-25T17:34:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cbl-514-caliway-biopharmaceutics-cellulite-likelihood-of-approval-2/ 2024-12-25T17:33:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/botensilimab-agenus-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval-2/ 2024-12-25T17:33:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hymecromone-halo-biosciences-interstitial-lung-diseases-diffuse-parenchymal-lung-disease-likelihood-of-approval-2/ 2025-01-19T17:50:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hymecromone-halo-biosciences-primary-sclerosing-cholangitis-likelihood-of-approval-2/ 2025-01-19T17:49:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/quemliclustat-arcus-biosciences-pancreatic-ductal-adenocarcinoma-likelihood-of-approval-2/ 2024-12-25T17:29:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jaktinib-hydrochloride-suzhou-zelgen-biopharmaceutical-post-polycythemia-vera-myelofibrosis-ppv-mf-likelihood-of-approval/ 2025-01-19T17:49:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jaktinib-hydrochloride-suzhou-zelgen-biopharmaceutical-chronic-idiopathic-myelofibrosis-primary-myelofibrosis-likelihood-of-approval/ 2024-07-05T05:17:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/izalontamab-systimmune-lung-adenocarcinoma-likelihood-of-approval-2/ 2024-12-25T17:29:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/izalontamab-systimmune-oral-cavity-mouth-cancer-likelihood-of-approval-2/ 2024-12-25T17:29:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/izalontamab-systimmune-oropharyngeal-cancer-likelihood-of-approval-2/ 2024-12-25T17:29:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/izalontamab-systimmune-nasopharyngeal-cancer-likelihood-of-approval-2/ 2024-12-25T17:29:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/izalontamab-systimmune-laryngeal-cancer-likelihood-of-approval-2/ 2024-12-25T17:29:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/izalontamab-systimmune-hypopharyngeal-cancer-likelihood-of-approval-2/ 2024-12-25T17:29:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/izalontamab-systimmune-colon-cancer-likelihood-of-approval-2/ 2024-12-25T17:29:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bt-5528-bicycle-therapeutics-esophageal-cancer-likelihood-of-approval-2/ 2024-12-25T17:29:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bt-5528-bicycle-therapeutics-pancreatic-cancer-likelihood-of-approval-2/ 2024-12-25T17:29:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tld-1433-theralase-technologies-non-muscle-invasive-bladder-cancer-nmibc-superficial-bladder-cancer-likelihood-of-approval-2/ 2025-01-19T17:48:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lisaftoclax-ascentage-pharma-group-international-acute-myelocytic-leukemia-aml-acute-myeloblastic-leukemia-likelihood-of-approval-2/ 2024-12-25T17:29:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/budigalimab-abbvie-metastatic-adenocarcinoma-of-the-pancreas-likelihood-of-approval-2/ 2024-12-25T17:28:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bentracimab-serb-bleeding-and-clotting-disorders-likelihood-of-approval-2/ 2024-12-25T17:28:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/uncategorized/arsenic-trioxide-syros-pharmaceuticals-acute-promyelocytic-leukemia-likelihood-of-approval-2/ 2023-10-27T21:49:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atrn-119-aprea-therapeutics-ovarian-cancer-likelihood-of-approval-3/ 2024-02-08T03:12:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/uncategorized/atrn-119-aprea-therapeutics-ovarian-cancer-likelihood-of-approval-2/ 2023-10-27T21:44:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ibrutinib-abbvie-renal-cell-carcinoma-likelihood-of-approval/ 2024-05-20T01:57:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trametinib-dimethyl-sulfoxide-novartis-hairy-cell-leukemia-likelihood-of-approval-2/ 2024-12-25T17:18:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mrg-002-shanghai-miracogen-bladder-cancer-likelihood-of-approval-2/ 2024-12-25T17:18:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/enfortumab-vedotin-astellas-pharma-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval-2/ 2024-12-25T17:24:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/enfortumab-vedotin-astellas-pharma-transitional-cell-carcinoma-urothelial-cell-carcinoma-likelihood-of-approval-2/ 2024-12-25T17:24:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/guadecitabine-sodium-astex-pharmaceuticals-small-cell-lung-cancer-likelihood-of-approval-2/ 2024-12-25T17:18:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vatiquinone-ptc-therapeutics-melas-syndrome-mitochondrial-encephalomyopathy-lactic-acidosis-and-stroke-like-episodes-likelihood-of-approval-2/ 2024-12-25T17:24:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vatiquinone-ptc-therapeutics-subacute-necrotizing-encephalomyelopathy-leigh-disease-likelihood-of-approval-2/ 2024-12-25T17:23:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vatiquinone-ptc-therapeutics-friedreich-ataxia-likelihood-of-approval-2/ 2024-12-25T17:23:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/venglustat-malate-sanofi-gaucher-disease-type-iii-likelihood-of-approval-2/ 2025-01-19T17:20:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aglatimagene-besadenovec-candel-therapeutics-pancreatic-ductal-adenocarcinoma-likelihood-of-approval-2/ 2024-12-25T17:17:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/avutometinib-potassium-verastem-peritoneal-cancer-likelihood-of-approval-2/ 2024-12-25T17:17:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anv-419-anaveon-esophageal-cancer-likelihood-of-approval-2/ 2024-12-25T17:16:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/signal-sanofi-becomes-latest-pharma-giant-to-spin-off-consumer-healthcare-business/ 2023-10-27T16:01:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jnj-8543-johnson-johnson-waldenstrom-macroglobulinemia-lymphoplasmacytic-lymphoma-likelihood-of-approval-2/ 2024-12-25T17:16:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/uncategorized/ds-9606a-daiichi-sankyo-metastatic-ovarian-cancer-likelihood-of-approval-2/ 2023-10-27T15:57:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/santhera-secures-fda-approval-for-duchenne-muscular-dystrophy-therapy/ 2023-10-27T15:50:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/venture-financing-targeted-protein-degraders/ 2023-10-27T14:00:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/csls-haemophilia-b-therapy-hemgenix-scores-win-authorisation-in-canada/ 2023-11-02T11:23:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/eli-lillys-omvoh-scores-fda-approval-for-ulcerative-colitis-after-past-rejection/ 2023-10-27T12:56:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-accepts-bla-resubmission-for-immunitybios-bladder-cancer-therapy/ 2023-10-27T10:38:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/nice-abbvie-parkinsons-treatment/ 2023-10-27T10:23:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/china-viiv-healthcare-vocabria-rekambys-hiv-1/ 2023-10-27T09:45:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-approval-roche-rvo/ 2023-10-27T08:23:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/georgiamune-verily-partner-cancer-treatment/ 2023-10-27T07:50:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/cphi-europe-taking-the-lessons-of-covid-19-to-the-next-frontier/ 2023-10-31T09:23:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/obx-115-obsidian-therapeutics-metastatic-melanoma-likelihood-of-approval-2/ 2024-12-25T17:16:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anv-419-anaveon-metastatic-melanoma-likelihood-of-approval-2/ 2024-12-25T17:16:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ranibizumab-sr-f-hoffmann-la-roche-diabetic-macular-edema-likelihood-of-approval-2/ 2024-12-25T17:15:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tagraxofusp-stemline-therapeutics-hypereosinophilic-syndrome-likelihood-of-approval-2/ 2024-12-25T17:15:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/uncategorized/eflornithine-panbela-therapeutics-gastric-cancer-likelihood-of-approval-2/ 2023-10-27T05:19:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/irl-201104-revolo-biotherapeutics-eosinophilic-esophagitis-likelihood-of-approval-2/ 2024-12-25T17:15:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jnj-8543-johnson-johnson-follicular-lymphoma-likelihood-of-approval-2/ 2024-12-25T17:15:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/iae-0972-sunho-china-biopharmaceutical-squamous-non-small-cell-lung-cancer-likelihood-of-approval-2/ 2024-12-25T17:14:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ad-109-apnimed-obstructive-sleep-apnea-likelihood-of-approval-2/ 2025-01-19T17:01:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/shra-1904-jiangsu-hengrui-medicine-gastric-cancer-likelihood-of-approval-2/ 2024-12-25T17:14:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ensomafusp-alfa-f-hoffmann-la-roche-marginal-zone-b-cell-lymphoma-likelihood-of-approval-2/ 2024-12-25T17:14:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ensomafusp-alfa-f-hoffmann-la-roche-diffuse-large-b-cell-lymphoma-likelihood-of-approval-2/ 2024-12-25T17:14:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anv-419-anaveon-renal-cell-carcinoma-likelihood-of-approval-2/ 2024-12-25T17:13:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vlx-1005-veralox-therapeutics-heparin-induced-thrombocytopenia-likelihood-of-approval-2/ 2024-12-25T17:13:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mbx-2109-mbx-biosciences-inc-hypoparathyroidism-likelihood-of-approval-2/ 2024-09-09T01:50:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mrna-1010-moderna-seasonal-influenza-likelihood-of-approval-2/ 2025-01-19T16:59:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/shra-1904-jiangsu-hengrui-medicine-gastroesophageal-ge-junction-carcinomas-likelihood-of-approval-2/ 2024-12-25T17:13:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/shra-1904-jiangsu-hengrui-medicine-pancreatic-cancer-likelihood-of-approval-2/ 2024-12-25T17:13:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jnj-8543-johnson-johnson-splenic-marginal-zone-b-cell-lymphoma-likelihood-of-approval-2/ 2024-12-25T17:12:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mb-106-mustang-bio-relapsed-chronic-lymphocytic-leukemia-cll-likelihood-of-approval-2/ 2024-12-25T17:12:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/shra-1904-jiangsu-hengrui-medicine-solid-tumor-likelihood-of-approval-2/ 2024-12-25T17:11:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/and-017-kind-pharmaceuticals-anemia-in-chronic-kidney-disease-renal-anemia-likelihood-of-approval-2/ 2024-12-25T17:11:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/blinatumomab-amgen-lymphoblastic-lymphoma-likelihood-of-approval-2/ 2024-12-25T17:11:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mb-106-mustang-bio-follicular-lymphoma-likelihood-of-approval-2/ 2024-12-25T17:09:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mb-106-mustang-bio-diffuse-large-b-cell-lymphoma-likelihood-of-approval-2/ 2024-12-25T17:09:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/survodutide-boehringer-ingelheim-international-obesity-likelihood-of-approval-2/ 2024-12-25T17:11:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anv-419-anaveon-non-small-cell-lung-cancer-likelihood-of-approval-2/ 2024-12-25T17:09:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/camrelizumab-jiangsu-hengrui-medicine-triple-negative-breast-cancer-tnbc-likelihood-of-approval-2/ 2024-12-25T17:09:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mrg-002-shanghai-miracogen-metastatic-transitional-urothelial-tract-cancer-likelihood-of-approval-2/ 2024-12-25T17:08:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vonoprazan-acetate-jiangsu-carephar-pharmaceutical-duodenal-ulcer-likelihood-of-approval-2/ 2025-01-19T16:56:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/uncategorized/hcw-9218-hcw-biologics-breast-cancer-likelihood-of-approval-2/ 2023-10-27T03:53:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/psilocybin-compass-pathways-treatment-resistant-depression-likelihood-of-approval/ 2025-01-19T16:56:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/botensilimab-agenus-metastatic-colorectal-cancer-likelihood-of-approval-2/ 2024-12-25T17:08:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/uncategorized/elimusertib-bayer-ovarian-cancer-likelihood-of-approval-2/ 2023-10-27T03:49:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bt-5528-bicycle-therapeutics-transitional-cell-cancer-urothelial-cell-cancer-likelihood-of-approval-2/ 2024-12-25T17:08:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anv-419-anaveon-hepatocellular-carcinoma-likelihood-of-approval-2/ 2024-12-25T17:10:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/botensilimab-agenus-colorectal-cancer-likelihood-of-approval-2/ 2024-12-25T17:08:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mti-201-modulation-therapeutics-metastatic-uveal-melanoma-likelihood-of-approval-2/ 2024-12-25T17:08:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mrg-002-shanghai-miracogen-human-epidermal-growth-factor-receptor-2-positive-breast-cancer-her2-breast-cancer-likelihood-of-approval-2/ 2024-12-25T17:08:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anv-419-anaveon-pancreatic-cancer-likelihood-of-approval-2/ 2024-12-25T17:10:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anv-419-anaveon-colorectal-cancer-likelihood-of-approval-2/ 2024-12-25T17:08:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sotorasib-amgen-colorectal-cancer-likelihood-of-approval-2/ 2024-12-25T17:08:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/amy-101-amyndas-pharmaceuticals-glomerulonephritis-likelihood-of-approval-2/ 2024-09-09T01:43:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/feladilimab-gsk-squamous-non-small-cell-lung-cancer-likelihood-of-approval-2/ 2024-12-25T17:08:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/valemetostat-daiichi-sankyo-peripheral-t-cell-lymphomas-ptcl-likelihood-of-approval-2/ 2024-12-25T17:08:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/epeleuton-afimmune-biopharma-sickle-cell-disease-likelihood-of-approval-2/ 2024-12-25T17:07:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/patritumab-deruxtecan-daiichi-sankyo-triple-negative-breast-cancer-tnbc-likelihood-of-approval-2/ 2024-12-25T17:05:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/enfortumab-vedotin-astellas-pharma-epithelial-ovarian-cancer-likelihood-of-approval-2/ 2024-12-25T17:05:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/patritumab-deruxtecan-daiichi-sankyo-metastatic-breast-cancer-likelihood-of-approval-2/ 2024-12-25T17:04:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/radspherin-oncoinvent-peritoneal-cancer-likelihood-of-approval-2/ 2024-12-25T17:07:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jaktinib-hydrochloride-suzhou-zelgen-biopharmaceutical-ankylosing-spondylitis-bekhterev-s-disease-likelihood-of-approval/ 2025-01-19T16:53:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/odronextamab-regeneron-pharmaceuticals-diffuse-large-b-cell-lymphoma-likelihood-of-approval-2/ 2024-12-25T17:04:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cetuximab-biobetter-shanghai-henlius-biotech-squamous-non-small-cell-lung-cancer-likelihood-of-approval-2/ 2024-12-25T17:07:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/seralutinib-gossamer-bio-pulmonary-arterial-hypertension-likelihood-of-approval-2/ 2024-12-25T17:07:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/siremadlin-succinate-novartis-post-polycythemia-vera-myelofibrosis-ppv-mf-likelihood-of-approval-2/ 2024-12-25T17:04:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/livmoniplimab-abbvie-non-small-cell-lung-cancer-likelihood-of-approval-2/ 2024-12-25T17:04:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/etrasimod-pfizer-eosinophilic-esophagitis-likelihood-of-approval-2/ 2024-12-25T17:04:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/uncategorized/nktr-255-nektar-therapeutics-metastatic-transitional-urothelial-tract-cancer-likelihood-of-approval-2/ 2023-10-27T02:52:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ranibizumab-sr-f-hoffmann-la-roche-diabetic-retinopathy-likelihood-of-approval-2/ 2024-12-25T17:06:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/camrelizumab-jiangsu-hengrui-medicine-gastric-cancer-likelihood-of-approval-2/ 2024-12-25T17:04:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/izalontamab-systimmune-triple-negative-breast-cancer-tnbc-likelihood-of-approval-2/ 2024-12-25T17:06:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mezagitamab-takeda-pharmaceutical-idiopathic-thrombocytopenic-purpura-immune-thrombocytopenic-purpura-likelihood-of-approval/ 2024-07-05T01:28:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/selinexor-karyopharm-therapeutics-burkitt-lymphoma-likelihood-of-approval-2/ 2024-12-25T17:04:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/paltusotine-hydrochloride-crinetics-pharmaceuticals-carcinoid-syndrome-malignant-carcinoid-syndrome-likelihood-of-approval-2/ 2025-01-19T16:52:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rituximab-biosimilar-shanghai-henlius-biotech-splenic-marginal-zone-b-cell-lymphoma-likelihood-of-approval-2/ 2024-12-25T17:06:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ifinatamab-deruxtecan-daiichi-sankyo-small-cell-lung-cancer-likelihood-of-approval-2/ 2024-12-25T17:06:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/imnn-001-imunon-epithelial-ovarian-cancer-likelihood-of-approval-2/ 2024-09-09T01:41:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/siremadlin-succinate-novartis-post-essential-thrombocythemia-myelofibrosis-post-et-mf-likelihood-of-approval-2/ 2024-12-25T17:03:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/siremadlin-succinate-novartis-myelofibrosis-likelihood-of-approval-2/ 2024-12-25T17:03:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/selinexor-karyopharm-therapeutics-myelofibrosis-likelihood-of-approval-2/ 2024-12-25T17:02:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/satralizumab-f-hoffmann-la-roche-demyelinating-diseases-likelihood-of-approval-2/ 2024-12-25T17:02:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/enfortumab-vedotin-astellas-pharma-fallopian-tube-cancer-likelihood-of-approval-2/ 2024-12-25T17:02:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/garadacimab-csl-idiopathic-pulmonary-fibrosis-likelihood-of-approval-2/ 2024-12-25T17:02:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/onvansertib-fumarate-cardiff-oncology-metastatic-colorectal-cancer-likelihood-of-approval-2/ 2024-12-25T17:02:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vemurafenib-f-hoffmann-la-roche-neuroblastoma-likelihood-of-approval-2/ 2024-12-25T17:02:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/feladilimab-gsk-non-small-cell-lung-cancer-likelihood-of-approval-2/ 2024-12-25T17:01:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/navtemadlin-kartos-therapeutics-relapsed-acute-myeloid-leukemia-likelihood-of-approval-2/ 2024-12-25T17:01:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/vietnam-fdi-growth-ten-months-2023/ 2023-10-26T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ukraine-ukrposhta-30-million-euro-investment/ 2023-10-26T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/european-commission-bolsters-defences-against-critical-medicine-shortages/ 2023-10-26T17:07:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/pfizer-and-biontech-post-early-win-for-combination-covid-19-flu-vaccine/ 2023-10-26T15:19:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/fda-approves-tofidence-bio-theras/ 2023-10-26T13:40:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/triventi-secures-92m-to-advance-clinical-development-of-antibody-therapy/ 2023-10-26T12:25:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/myth-busting-do-activated-carbon-filters-deliver-on-their-promise-to-improve-air-hygiene-for-bacteria-and-viruses/ 2023-10-26T11:22:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/takeda-lowers-fy2023-profit-forecasts-after-pipeline-setbacks/ 2023-10-26T12:39:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/appili-biodefence-vaccine-development/ 2023-10-26T10:40:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/zenith-cencora-zen-3694/ 2023-10-26T10:12:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/msd-terminates-phase-ii-trials-for-alzheimers-drug-due-to-liver-toxicity/ 2023-10-26T12:11:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/how-gene-therapies-can-transform-sickle-cell-disease-treatment/ 2023-11-02T11:23:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/gsk-rsv-vaccine-arexvy-50-59/ 2023-10-26T09:09:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/us-bavarian-nordic-mpox-vaccine/ 2023-10-26T08:22:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/flashpoint-funds-nanotech-medicines/ 2023-10-26T08:24:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/cphi-europe-pharma-companies-fail-to-engage-patients-early-in-drug-development/ 2023-10-31T09:24:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/carfostin-asklepios-biopharmaceutical-congestive-heart-failure-heart-failure-likelihood-of-approval-2/ 2024-12-25T17:00:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cbp-501-canbas-pancreatic-cancer-likelihood-of-approval-2/ 2024-12-25T17:00:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/contezolid-micurx-pharmaceuticals-diabetic-foot-infection-dfi-likelihood-of-approval/ 2024-09-09T01:39:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/enfortumab-vedotin-astellas-pharma-peritoneal-cancer-likelihood-of-approval-2/ 2024-12-25T17:00:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/defactinib-hydrochloride-verastem-ovarian-cancer-likelihood-of-approval-2/ 2024-12-25T17:00:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/margetuximab-macrogenics-gallbladder-cancer-likelihood-of-approval/ 2024-02-08T02:04:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rintatolimod-aim-immunotech-melanoma-likelihood-of-approval-2/ 2024-12-25T16:59:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/dashboards/deals-dashboards/theuk-privateequity-activity-pharmaceutical-industry/ 2024-12-02T16:27:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tertomotide-gemvax-kael-alzheimer-s-disease-likelihood-of-approval-2/ 2024-12-25T16:59:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cd19-targeted-car-t-therapy-chongqing-precision-biotech-dermatomyositis-likelihood-of-approval/ 2025-01-20T16:19:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cd19-targeted-car-t-therapy-chongqing-precision-biotech-sicca-syndrome-sjogren-likelihood-of-approval/ 2025-01-20T16:19:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cd19-targeted-car-t-therapy-chongqing-precision-biotech-anti-neutrophil-cytoplasmic-antibody-associated-vasculitis-anca-vasculitis-likelihood-of-approval/ 2025-01-20T16:19:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cd19-targeted-car-t-therapy-chongqing-precision-biotech-systemic-sclerosis-scleroderma-likelihood-of-approval/ 2025-01-20T16:19:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cd19-targeted-car-t-therapy-chongqing-precision-biotech-systemic-lupus-erythematosus-likelihood-of-approval/ 2025-01-20T16:19:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bi-771716-boehringer-ingelheim-international-geographic-atrophy-likelihood-of-approval/ 2024-07-05T06:29:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tagraxofusp-stemline-therapeutics-myelofibrosis-likelihood-of-approval-2/ 2024-12-25T16:58:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bnt-166a-biontech-monkeypox-likelihood-of-approval/ 2023-10-26T04:18:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sirolimus-pfizer-growth-disorders-likelihood-of-approval/ 2024-07-05T01:25:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mk-5720-merck-schizophrenia-likelihood-of-approval/ 2023-10-26T04:16:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vemurafenib-f-hoffmann-la-roche-thyroid-cancer-likelihood-of-approval-2/ 2024-12-25T16:58:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mrna-1403-moderna-norovirus-infections-likelihood-of-approval/ 2024-06-14T04:24:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mrna-1405-moderna-norovirus-infections-likelihood-of-approval/ 2024-06-14T04:24:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ustekinumab-biosimilar-rani-therapeutics-psoriatic-arthritis-likelihood-of-approval/ 2024-09-09T04:25:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tagraxofusp-stemline-therapeutics-systemic-mastocytosis-likelihood-of-approval-2/ 2024-12-25T16:58:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ustekinumab-biosimilar-rani-therapeutics-psoriasis-likelihood-of-approval/ 2024-09-09T04:25:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/uncategorized/sirolimus-albumin-bound-aadi-bioscience-bladder-cancer-likelihood-of-approval-2/ 2023-10-26T04:06:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trn-213-tris-pharma-muscle-spasticity-likelihood-of-approval/ 2025-01-20T16:19:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/neratinib-puma-biotechnology-pancreatic-cancer-likelihood-of-approval-2/ 2024-12-25T16:58:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hh-006-huahui-health-hepatitis-b-likelihood-of-approval/ 2024-07-05T06:29:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mwtx-01-disc-medicine-beta-thalassaemia-likelihood-of-approval/ 2025-01-20T16:19:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mwtx-01-disc-medicine-polycythemia-vera-likelihood-of-approval/ 2025-01-20T16:19:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sodium-thiosulfate-byondis-drug-toxicity-likelihood-of-approval/ 2023-10-26T04:00:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trametinib-dimethyl-sulfoxide-novartis-relapsed-multiple-myeloma-likelihood-of-approval-2/ 2024-12-25T16:58:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vemurafenib-f-hoffmann-la-roche-sarcomas-likelihood-of-approval-2/ 2024-12-25T16:58:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nb-003-newbay-medical-technology-gastrointestinal-stromal-tumor-gist-likelihood-of-approval/ 2024-09-09T04:25:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ck-0045-cytoki-pharma-inflammatory-bowel-disease-likelihood-of-approval/ 2025-01-20T16:19:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ck-0045-cytoki-pharma-obesity-likelihood-of-approval/ 2025-01-20T16:18:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/neratinib-puma-biotechnology-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval-2/ 2024-12-25T16:58:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/neratinib-puma-biotechnology-esophageal-cancer-likelihood-of-approval-2/ 2024-12-25T16:58:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/stromel-akan-biosciences-osteoarthritis-likelihood-of-approval/ 2025-01-20T16:18:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ns-229-nippon-shinyaku-granulomatosis-with-polyangiitis-wegener-s-granulomatosis-likelihood-of-approval/ 2025-01-20T16:18:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vip-943-vincerx-pharma-b-cell-acute-lymphocytic-leukemia-b-cell-acute-lymphoblastic-leukaemia-likelihood-of-approval/ 2025-01-20T16:18:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vip-943-vincerx-pharma-relapsed-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-20T16:18:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vip-943-vincerx-pharma-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-20T16:18:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vip-943-vincerx-pharma-myelodysplastic-syndrome-likelihood-of-approval/ 2025-01-20T16:18:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sildenafil-citrate-aspargo-laboratories-erectile-dysfunction-likelihood-of-approval/ 2023-10-26T03:49:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bread-01-brexogen-atopic-dermatitis-atopic-eczema-likelihood-of-approval/ 2025-01-20T16:18:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/neratinib-puma-biotechnology-ovarian-cancer-likelihood-of-approval-2/ 2024-12-25T16:57:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gm-1020-gilgamesh-pharmaceuticals-major-depressive-disorder-likelihood-of-approval/ 2024-09-09T04:25:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ro-7185876-f-hoffmann-la-roche-alzheimer-s-disease-likelihood-of-approval/ 2023-10-26T03:45:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/amitriptyline-hydrochloride-algotherapeutix-chemotherapy-induced-peripheral-neuropathy-likelihood-of-approval/ 2025-01-20T16:18:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/neratinib-puma-biotechnology-gastric-cancer-likelihood-of-approval-2/ 2024-12-25T16:57:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dkf-340-dongkook-pharmaceutical-inflammation-likelihood-of-approval/ 2023-10-26T03:39:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ang-003-anagram-therapeutics-exocrine-pancreatic-insufficiency-likelihood-of-approval/ 2024-02-08T04:11:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/incb-099280-incyte-colorectal-cancer-likelihood-of-approval/ 2025-01-20T16:18:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/avutometinib-potassium-verastem-ovarian-cancer-likelihood-of-approval-2/ 2024-12-25T16:57:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/y-3-neurodawn-pharmaceutical-depression-likelihood-of-approval/ 2025-01-20T16:18:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sgr-2921-schrodinger-relapsed-acute-myeloid-leukemia-likelihood-of-approval/ 2024-09-09T04:24:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sgr-2921-schrodinger-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2024-09-09T04:24:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sgr-2921-schrodinger-myelodysplastic-syndrome-likelihood-of-approval/ 2024-09-09T04:24:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/buntanetap-tartrate-annovis-bio-alzheimer-s-disease-likelihood-of-approval-2/ 2024-12-25T16:56:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/meplazumab-jiangsu-pacific-meinuoke-bio-pharmarceutical-malaria-likelihood-of-approval/ 2025-01-20T16:18:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/arlocabtagene-autoleucel-bristol-myers-squibb-refractory-multiple-myeloma-likelihood-of-approval/ 2024-05-20T03:29:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/arlocabtagene-autoleucel-bristol-myers-squibb-relapsed-multiple-myeloma-likelihood-of-approval/ 2024-05-20T03:29:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/subasumstat-takeda-pharmaceutical-waldenstrom-macroglobulinemia-lymphoplasmacytic-lymphoma-likelihood-of-approval/ 2024-06-19T15:59:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/subasumstat-takeda-pharmaceutical-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-06-19T15:59:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cvn-293-cerevance-amyotrophic-lateral-sclerosis-likelihood-of-approval/ 2025-01-20T16:18:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cvn-293-cerevance-alzheimer-s-disease-likelihood-of-approval/ 2025-01-20T16:18:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brigimadlin-boehringer-ingelheim-international-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-04-20T04:44:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lepodisiran-sodium-eli-lilly-and-co-atherosclerosis-likelihood-of-approval/ 2025-01-20T16:17:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/iptacopan-hydrochloride-novartis-membranoproliferative-glomerulonephritis-mesangiocapillary-glomerulonephritis-likelihood-of-approval/ 2025-01-20T16:17:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/plozasiran-sodium-arrowhead-pharmaceuticals-familial-chylomicronemia-type-i-hyperlipoproteinemia-likelihood-of-approval/ 2025-01-20T16:17:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/plozasiran-sodium-arrowhead-pharmaceuticals-hypertriglyceridemia-likelihood-of-approval/ 2025-01-20T16:17:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zeteletinib-adipate-boston-pharmaceuticals-medullary-thyroid-cancer-likelihood-of-approval/ 2025-01-20T16:17:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tildacerfont-spruce-biosciences-polycystic-ovarian-syndrome-likelihood-of-approval/ 2024-09-09T04:23:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ceftibuten-ledaborbactam-etzadroxil-venatorx-pharmaceuticals-enterobacteriaceae-infections-likelihood-of-approval/ 2024-06-14T04:22:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/omo-103-peptomyc-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2025-01-20T16:17:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mb-105-march-biosciences-peripheral-t-cell-lymphomas-ptcl-likelihood-of-approval/ 2025-01-20T16:17:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mb-105-march-biosciences-anaplastic-large-cell-lymphoma-alcl-likelihood-of-approval/ 2025-01-20T16:17:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/donidalorsen-sodium-ionis-pharmaceuticals-hereditary-angioedema-hae-c1-esterase-inhibitor-c1-inh-deficiency-likelihood-of-approval/ 2024-06-14T04:22:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lisaftoclax-ascentage-pharma-group-international-refractory-multiple-myeloma-likelihood-of-approval/ 2025-01-20T16:17:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lisaftoclax-ascentage-pharma-group-international-relapsed-multiple-myeloma-likelihood-of-approval/ 2025-01-20T16:17:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ezabenlimab-boehringer-ingelheim-international-colorectal-cancer-likelihood-of-approval/ 2025-01-20T16:17:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tifcemalimab-shanghai-junshi-biosciences-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-20T16:17:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rosnilimab-anaptysbio-rheumatoid-arthritis-likelihood-of-approval/ 2025-01-20T16:17:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nesuparib-onconic-therapeutics-epithelial-ovarian-cancer-likelihood-of-approval/ 2025-01-20T16:17:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nesuparib-onconic-therapeutics-peritoneal-cancer-likelihood-of-approval/ 2025-01-20T16:17:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nesuparib-onconic-therapeutics-fallopian-tube-cancer-likelihood-of-approval/ 2025-01-20T16:17:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/efzofitimod-atyr-pharma-interstitial-lung-diseases-diffuse-parenchymal-lung-disease-likelihood-of-approval/ 2025-01-20T16:16:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/efzofitimod-atyr-pharma-systemic-sclerosis-scleroderma-likelihood-of-approval/ 2025-01-20T16:16:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/uncategorized/aminolevulinic-acid-hydrochloride-photonamic-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2023-10-26T01:56:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/denifanstat-sagimet-biosciences-liver-cirrhosis-likelihood-of-approval/ 2025-01-20T16:16:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/satralizumab-f-hoffmann-la-roche-graves-ophthalmopathy-likelihood-of-approval/ 2025-01-20T16:16:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/imnn-001-imunon-epithelial-tumor-likelihood-of-approval/ 2024-09-09T04:20:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/imnn-001-imunon-adenocarcinoma-likelihood-of-approval/ 2024-09-09T04:20:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/imnn-001-imunon-peritoneal-cancer-likelihood-of-approval/ 2024-09-09T04:20:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/imnn-001-imunon-endometrial-cancer-likelihood-of-approval/ 2024-09-09T04:20:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/imnn-001-imunon-fallopian-tube-cancer-likelihood-of-approval/ 2024-09-09T04:20:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/apocell-enlivex-therapeutics-osteoarthritis-likelihood-of-approval/ 2025-01-20T16:16:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ofatumumab-novartis-relapsing-remitting-multiple-sclerosis-rrms-likelihood-of-approval/ 2024-06-14T04:19:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pepinemab-vaccinex-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2025-01-20T16:16:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/saudi-arabia-fdi-inflow-down-21-2-percent-yoy/ 2023-10-25T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/cphi-europe-quality-improvements-key-for-the-surviving-the-generic-drugs-market/ 2023-10-31T09:25:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/aiolos-launches-with-245m-series-a-to-advance-asthma-therapies/ 2023-10-25T17:01:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/annovis-looks-to-advance-pivotal-alzheimers-and-parkinsons-drug-studies/ 2023-10-25T16:11:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/axosim-acquires-microbrain-technology-to-build-neurological-drug-pipeline/ 2023-10-25T14:26:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/international-initiative-launched-to-create-personalised-cardiovascular-care/ 2023-10-25T12:31:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/dermbiont-raises-35-2m-in-series-b-for-dermatological-therapies/ 2023-10-25T10:53:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/novartis-q3-2023-income/ 2023-10-25T10:22:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/insmed-ai-drug-development/ 2023-10-25T10:31:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-servier-tibsovo-mds/ 2023-10-25T07:57:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/bms-breakthrough-therapy-designation-ppf/ 2023-10-25T08:18:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/malaysia-japan-inbound-fdi-2023/ 2023-10-24T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/lebanon-totalenergies-offshore-well/ 2023-10-24T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/cphi-europe-cdmos-prioritise-innovation-and-flexibility-in-an-evolving-landscape/ 2023-10-31T09:25:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/trial-sponsors-say-cros-need-to-own-their-mistakes-and-take-responsibility/ 2023-10-25T11:02:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/israel-hamas-impact-pharma-manufacturers/ 2023-10-24T15:14:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/az-and-daiichi-score-another-win-with-enhertus-eu-approval-in-lung-cancer/ 2023-10-24T15:06:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-cracks-down-on-off-label-drug-use-messaging/ 2023-10-24T14:48:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/addf-announces-speech-database-to-identify-biomarkers-for-alzheimers/ 2023-10-24T14:43:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/sponsors-urged-to-compensate-oncology-patients-and-meet-trial-staff-face-to-face/ 2023-10-24T13:49:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/hdt-bio-navigates-vaccine-strategy-in-a-changing-covid-19-landscape/ 2023-10-24T13:15:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/certa-wins-fda-orphan-drug-designation-for-scleroderma-therapy/ 2023-10-24T10:58:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/astraveus-wins-e10-4m-french-grant-to-advance-cgt-manufacturing/ 2023-10-25T09:46:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/invo-naya-merger-life-science/ 2023-10-24T10:42:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/genexine-kgbio-drug-approval/ 2023-10-24T10:02:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/comment/ai-in-pharma-qa-with-globaldata-thematic-analyst/ 2023-11-02T16:33:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/samsung-biologics-kurma/ 2023-10-25T06:27:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/sumitomo-prostate-cancer-treatment/ 2023-10-24T08:37:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/pear-therapeutics-a-lesson-for-future-dtx-developers/ 2023-10-24T07:21:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/turner-townsend-baesl-mro-facility/ 2023-10-23T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/voxzogo-given-green-light-to-treat-children-under-five-by-us-fda/ 2023-10-23T17:59:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/liver-specialist-aligos-scores-92m-in-private-placement-funding/ 2023-10-23T17:51:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/delbag-nordic-air-now-hengst-filtration/ 2023-10-24T09:29:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/amerisourcebergen-access-h2o-therapeutics-parky-dtx-app/ 2023-10-23T15:59:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/eli-lilly-fda-crl-lebrikizumab/ 2023-10-23T15:33:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/roche-to-buy-ulcerative-colitis-drug-from-roivant-for-7-1bn/ 2023-11-06T22:15:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/esmo2023-msd-welireg-leads-rcc-despite-unclear-os/ 2023-10-23T14:09:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/esmo2023-mirati-krazati-immuno-oncology-combo-to-shape-first-line-nsclc/ 2023-10-23T14:02:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-clears-pfizers-meningococcal-disease-vaccine/ 2023-10-23T13:51:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-approves-celltrions-subcutaneous-remicade-biosimilar-for-ibd/ 2023-10-26T08:33:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/what-is-quantum-computing-and-what-does-it-mean-for-business/ 2023-10-20T18:32:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ai-will-severely-impact-almost-a-fifth-of-jobs-indeed-says/ 2023-10-20T18:27:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/over-20000-uk-businesses-at-risk-of-chinese-espionage-warns-mi5-chief/ 2023-10-20T18:26:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/lipella-gets-go-ahead-for-trial-studying-chronic-oral-condition/ 2023-10-20T16:37:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/nvidia-banks-on-generative-ai-to-pursue-partnerships-with-biotechs/ 2023-10-20T16:00:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-clears-ucbs-bimzelx-for-psoriasis-treatment/ 2023-10-20T15:55:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/msd-signs-up-daiichi-sankyo-in-multibillion-dollar-deal-to-develop-adcs/ 2023-10-20T15:16:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/meilleur-partners-with-adni4-for-next-generation-alzheimers-biomarker/ 2023-10-20T12:50:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/roche-group-sales-rise-q3-2023/ 2023-10-20T11:07:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ec-pfizer-seagen-acquisition/ 2023-10-20T10:43:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/tourmaline-shifts-focus-to-developing-anti-il6-antibody-following-merger/ 2023-10-20T12:43:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/endeavor-acquires-rights-adc/ 2023-10-20T07:54:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/health-canada-noc-myfembree/ 2023-10-20T08:25:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/dashboards/jobs/environmentalsustainability-hiring-pharmaceutical-industry/ 2024-08-22T12:49:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/dashboards/jobs/socialresponsibility-hiring-pharmaceutical-industry-2/ 2024-08-22T12:49:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ec-expands-takedas-adcetris-label-for-advanced-hodgkin-lymphoma-treatment/ 2023-10-19T18:20:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/dashboards/jobs/hiring-north-american-pharma-industry/ 2023-10-19T17:12:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/dashboards/jobs/global-hiring-pharma-industry/ 2024-07-19T04:12:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/dashboards/jobs/hiring-us-pharma-industry/ 2023-10-19T17:11:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/dashboards/jobs/hiring-european-pharma-industry/ 2023-10-19T17:11:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/dashboards/jobs/hiring-british-pharma-industry/ 2023-10-19T17:11:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/dashboards/jobs/hiring-french-pharma-industry-4/ 2023-10-19T17:10:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/dashboards/jobs/hiring-german-pharma-industry/ 2023-10-19T17:10:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/uncategorized/hiring-french-pharma-industry-3/ 2023-10-19T17:07:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/uncategorized/hiring-french-pharma-industry-2/ 2023-10-19T17:05:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/dashboards/jobs/hiring-canadian-pharma-industry/ 2023-10-19T17:09:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/uncategorized/hiring-french-pharma-industry/ 2023-10-19T17:04:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/dashboards/jobs/hiring-belgian-pharma-industry/ 2023-10-19T17:09:16+00:00 daily 0.2